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Event History Analysis in Multivariate Longitudinal Data
Chaoyu Yuan
This thesis studies event history analysis in multivariate longitudinal observational
databases (LODs) and its application in postmarketing surveillance to identify and measure the
relationship between events of health outcomes and drug exposures. The LODs contain repeated
measurements on each individual whose healthcare information is recorded electronically. Novel
statistical methods are being developed to handle challenging issues arising from the scale and
complexity of postmarketing surveillance LODs. In particular, the self-controlled case series
(SCCS) method has been developed with two major features (1) it only uses individuals with at
least one event for analysis and inference and, (2) it uses each individual to be served as his/her
own control, effectively requiring a person to switch treatments during the observation period.
Although this method handles heterogeneity and bias, it does not take full advantage of the
observational databases. In this connection, the SCCS method may lead to a substantial loss of
efficiency.
We proposed a multivariate proportional intensity modeling approach with random effect
for multivariate LODs. The proposed method can explain the heterogeneity and eliminate bias in
LODs. It also handles multiple types of event cases and makes full use of the observational
databases. In the first part of this thesis, we present the multivariate proportional intensity model
with correlated frailty. We explore the correlation structure between multiple types of clinical
events and drug exposures. We introduce a multivariate Gaussian frailty to incorporate the
within-subject heterogeneity, i.e. hidden confounding factors. For parameter estimation, we adopt
the Bayesian approach using the Markov chain Monte Carlo method to get a series of samples
from the targeted full likelihood. We compare the new method with the SCCS method and some
frailty models through simulation studies. We apply the proposed model to an electronic health
record (EHR) dataset and identify event types as defined in Observational Outcomes Medical
Partnership (OMOP) project. We show that the proposed method outperforms the existing
methods in terms of common metrics, such as receiver operating characteristic (ROC) metrics.
Finally, we extend the proposed correlated frailty model to include a dynamic random effect. We
establish a general asymptotic theory for the nonparametric maximum likelihood estimators in
terms of identifiability, consistency, asymptotic normality and asymptotic efficiency. A detailed
illustration of the proposed method is done with the clinical event Myocardial Infarction (MI) and
drug treatment of Angiotensin-converting-enzyme (ACE) inhibitors, showing the dynamic effect
of unobserved heterogeneity.
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Event history analysis, also known as survival analysis, consists of statistical methods for the anal-
ysis of observational data on the occurrence and timing of events. In particular, an event can be
defined as a qualitative change that occurs at the time during the observation period, such as death,
marriage and birth. The event history analysis has found applications in many disciplines, includ-
ing sociology, bio-medicine and finance. The event history analysis can be useful in longitudinal
observational databases (LODs). The LODs collect repeated observations of the same study sub-
ject at the different time points. The subjects can be individuals, companies, groups and so on. The
analysis based on LODs can help with exploring patterns of change and the dynamics of individual
behaviors. This is important for understanding how subjects move from one situation to another.
Besides, proper analysis of the LODs can provide insights into causal mechanisms between ear-
lier history and later outcomes. Consequently, the healthcare LODs can be useful in drug safety
surveillance.
Recently, increased attention has been paid to drug safety in postmarketing surveillance, whose
task is to identify the unexpected adverse events (AE) caused by marketed drugs. Drug safety is
an important public health challenge, which caused 4.2− 30% of hospitalizations and cost approx-
imate 30.1 billion US dollars per year in the United States [33]. The drug safety process starts
with rigorous drug preapproval procedures implemented in randomized clinical trials. The limited
sample size in a clinical trial makes the detection of any adverse event difficult. The U.S. Food
and Drug Administration (FDA) keeps monitoring the drug safety after regulatory market autho-
rization, i.e. postmarketing surveillance. With much more diverse patients involved, increased
attention has been brought to the postmarketing surveillance methods to solve challenging drug
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safety problems.
The U.S. Food and Drug Administration (FDA) has been developing a system to identify and
detect adverse events of marketed drugs and other medical products. FDA relies on submission of
spontaneous reports in which clinicians or patients conclude that a drug may be the cause of some
certain adverse clinical events. These records and reports are submitted voluntarily from clinicians
or patients and will vary with their skills, experience, clinical history and existence of other plau-
sible explanations. Under-reporting, reports of known reactions and false causality attribution are
the common limitation of spontaneous reporting systems. Besides, spontaneous report system is a
passive surveillance system and often incomplete due to the rare occurrence of uncommon adverse
events and absence of control group for comparison. Some examples of spontaneous report sys-
tems are the international pharmacovigilance program of the World Health Organization (WHO),
the Yellow Card Scheme of the Medicines and Healthcare Products Regulatory Agency (MHRA)
and Adverse Event Reporting System (AERs) of the FDA.
Although spontaneous reporting system has its limitations, the FDA has established several
analytic methods for detecting causality between adverse events and marketed drugs based on it.
Disproportionality analysis is one of the most commonly used analytic methods for drug safety,
mostly relying on 2 × 2 summary tables, e.g. Table 1.1. Disproportionality methods focus on sev-
eral statistical measures of marginal association between adverse events and drug exposures. For
example, the Bayesian multi-item gamma-Poisson shrinker (MGPS, DuMouchel [6]) uses the sta-
tistical measure reporting ratio (RR) (in Table 1.2), which is the number of observed occurrences
with the adverse event and the drug exposure over the expected number of occurrences under inde-
pendent assumption. Besides MGPS, disproportionality methods include the Bayesian confidence
propagation neural network (BCPNN), the proportional reporting ratios (PRR) and the reporting
odds ratios (ROR). However, these methods may lead to biased results due to ignoring the con-
founding factors or dynamic effects because patients may take multiple drugs at the same time and
these drugs may have confounding effects.
2
𝐴𝐸 𝑗 = Yes 𝐴𝐸 𝑗 = Yes Total
𝐷𝑟𝑢𝑔𝑖 = Yes 𝑛00 = 20 𝑛01 = 100 120
𝐷𝑟𝑢𝑔𝑖 = No 𝑛10 = 100 𝑛11 = 980 1080
120 1080 1200
Table 1.1: An example of 2 × 2 spontaneous reports
Measure Statistical Formula
Reporting Ratio (RR) 𝑃(𝐴𝐸 |𝐷𝑟𝑢𝑔)𝑃(𝐴𝐸)
Proportional Reporting Ratio (PRR) 𝑃(𝐴𝐸 |𝐷𝑟𝑢𝑔)𝑃(𝐴𝐸 |𝑛𝑜𝑡𝐷𝑟𝑢𝑔)
Reporting Odds Ratio (ROR) 𝑃(𝐴𝐸 |𝐷𝑟𝑢𝑔)/𝑃(𝑛𝑜𝑡𝐴𝐸 |𝐷𝑟𝑢𝑔)𝑃(𝐴𝐸 |𝑛𝑜𝑡𝐷𝑟𝑢𝑔)/𝑃(𝑛𝑜𝑡𝐴𝐸 |𝑛𝑜𝑡𝐷𝑟𝑢𝑔)
Information Component (IC) log2
𝑃(𝐴𝐸 |𝐷𝑟𝑢𝑔)
𝑃(𝐴𝐸)
Table 1.2: Common measures of association for 2 × 2 spontaneous reports database
The spontaneous report system is a passive surveillance system with limitations as being dis-
cussed. To overcome these limitations, a new data source for active surveillance system called
longitudinal observational databases (LODs) has arisen in recent years. The information in LODs,
such as insurance claim databases and electronic health record (EHR) databases, are recorded
automatically instead of voluntary submission. LODs collect repeated observations of the same
study subject over a period. Specifically, LODs can record information of adverse events and drug
prescriptions. Based on LODs, novel machine learning and data mining algorithms have been
developed for postmarketing surveillance [23, 9, 18, 26, 27, 27, 28, 32]. In particular, the self-
controlled case series (SCCS) method [29, 30] was proposed for postmarketing surveillance since
it is the only statistical method with a rigorous theoretical backing for dealing with LODs. We will
introduce the approach with technical details in the subsequent sections.
The SCCS method is based on conditional Poisson regression to measure the causal association
between adverse events and drug exposures in postmarketing surveillance. Compared with other
regression methods, the SCCS method has two main features: (1) it only uses individuals with at
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least one event for analysis and, (2) each individual serves as his/her own control, thus requiring
each individual to have different exposure patterns.
Although SCCS related methods have achieved empirical success in postmarketing surveil-
lance with the Observational Medical Outcomes Partnership (OMOP) project, these methods still
have limitations due to model design:
• Low efficiency. The SCCS analysis only includes patients with at least one adverse event
and the information from the controls is not included. In addition, each case individual needs
to have different exposure patterns.
• Limited dependence structure. The SCCS methods require conditional independence as-
sumption between multiple event occurrences. However, such an assumption is likely to
be violated because the previous event occurrence can change the risk of future event. An
extension of the SCCS model is given by adding a positive term to the baseline event risk
[29]. This design of model may only work in very special situations and is not easy to be
extended to generalized cases.
• Failure in multivariate events. In the SCCS model setting, mathematical structure fails in
multivariate events unless each adverse event is treated as an independent model. Actually,
this is impractical in real world problems.
To address the above issues, we propose a multivariate random effect model based on event
history analysis. A central component of the multivariate random effect model is its flexible repre-
sentation form to describe the casual association between multiple events and correlation structure
of within-subject heterogeneity. Event history analysis, also known as survival analysis, consists
of statistical methods for the analysis of observational data on the occurrence and timing of events.
Below, we discuss the basic concepts and statistical models used in event history analysis.
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1.2 Survival Analysis Basics
In survival analysis, we are interested in survival time which is the time to a single event for each
individual, or more precisely the time elapsed from an initiating point to an event, or endpoint. Let
𝑇 be a nonnegative random variable representing survival time. We have some definitions.
• Survival function is the probability that the time of death or endpoint is later than some
specified time t:
𝑆(𝑡) = 𝑃𝑟 (𝑇 > 𝑡).
• Lifetime distribution function 𝐹 (𝑡) is the complement of the survival function and event
density function is the rate of death or failure events per unit time:
𝐹 (𝑡) =𝑃𝑟 (𝑇 ≤ 𝑡) = 1 − 𝑆(𝑡),
𝑓 (𝑡) =𝐹′(𝑡).
• Hazard function is defined as the event rate at time 𝑡 conditional on survival until time 𝑡 or
later (that is 𝑇 ≥ 𝑡). Specifically, an item has survived at time 𝑡 and we desire the probability





𝑃𝑟 (𝑡 ≤ 𝑇 < 𝑡 + 𝑑𝑡 |𝑇 ≥ 𝑡)
= lim
𝑑𝑡→0












𝜆(𝑠)𝑑𝑠 = − log 𝑆(𝑡).
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Figure 1.1: Survival times (×) and censoring times (o) in days.
1.2.1 Censoring
Censoring is one of the missing data problems in which time to event may not be fully observed
for some reasons such as termination of study. Censoring is common in survival analysis which
makes it special compared with ordinary linear regression or other standard statistical methods.
Right-censoring is the most common type of censoring, occurring when then survival time is "in-
complete" at the right side of the observation period. Event and censoring times of 10 individuals
are illustrated in Figure 1.1.
In the most standard analysis and methods, censoring is non-informative which means that
the time of censoring should be independent of the event time, given any observed covariates. A
similar but different concept is truncation, which may occur in certain follow-up studies.
We extend survival time to right-censored case. Let 𝑇 and 𝐶 denote the time elapsed from
an initiating event to an event and the end of the study, respectively. 𝐶 is also called censoring
time. Let 𝑇∗ = min(𝑇, 𝐶) be the follow up time and 𝛿 = 𝐼 ({𝑇 ≤ 𝐶}) be the status, a 0/1 indicator
which is 1 if survival time is observed and 0 if the observation is censored. What we actually
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observe is the pair (𝑇∗𝑖 , 𝛿𝑖) for individual 𝑖. Under the condition that the censoring is independent










𝜆(𝑇∗𝑖 )𝛿𝑖𝑆(𝑇∗𝑖 ). (1.1)
The counting process formulation replaces the pair of variables (𝑇∗𝑖 , 𝛿𝑖) with the pair of func-
tions (𝑁𝑖 (𝑡), 𝑌𝑖 (𝑡)), where
𝑁𝑖 (𝑡) = the number of observed events in [0, 𝑡] for unit 𝑖,
𝑌𝑖 (𝑡) =

1 unit 𝑖 is under observation and at risk at time 𝑡,
0 otherwise.
This formulation can be generalized to recurrent and multiple events, which will be introduced in
later sections.
1.2.2 Kaplan-Meier Estimator
The Kaplan-Meier estimator is a common nonparametric method to estimate the survival function
𝑆(𝑡) from a sample of censored survival data. Assume we have 𝑛 individuals and let 𝑡1 < 𝑡2 <
· · · < 𝑡𝑘 be the observed event times. Let 𝑑 𝑗 be the number of individuals who have an event at
time 𝑡 𝑗 and 𝑌𝑖 (𝑡) is at risk indicator function for individual i. Then the Kaplan-Meier estimator is a






𝑖=1𝑌𝑖 (𝑡 𝑗 )
).











𝑖=1𝑌𝑖 (𝑡 𝑗 ) (
∑𝑛
𝑖=1𝑌𝑖 (𝑡 𝑗 ) − 𝑑 𝑗 )
.
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1.2.3 Cox Proportion Hazards Regression Model
One objective of the survival analysis is to examine whether some features can affect survival
times. The Cox proportional hazards model is one of the most common regression models in
survival analysis, with hazard function [5]:
𝜆(𝑡; 𝑥) = 𝜆0(𝑡)𝑒𝛽𝑥 ,
where 𝜆0(𝑡) is the baseline hazard, 𝑥 is a covariate and 𝛽 is a parameter to be estimated, represent-
ing the relative effect of the covariate on the hazard function. The conditional survival function
can be estimated as
𝑆(𝑡; 𝑥) = [𝑆0(𝑡)]𝑒
𝛽𝑥
,
where 𝑆0(𝑡) = 𝑒−
∫ 𝑡
0 𝜆0 (𝑢)𝑑𝑢 .
Suppose that we have 𝑛 right-censored survival data {(𝑇∗𝑖 , 𝛿𝑖, 𝑋𝑖), 𝑖 = 1, · · · , 𝑛}. Recall the






















𝑌 𝑗 (𝑡 𝑗 )𝜆0(𝑡 𝑗 )𝑒𝛽𝑥 𝑗∑𝑛
𝑖=1𝑌𝑖 (𝑡 𝑗 )𝜆0(𝑡 𝑗 )𝑒𝛽𝑥𝑖
.
1.2.4 Extension
In the above discussion, we focus on the time to the occurrence of a single event for each individual.
However, there may be more complicated situations in real world problems. Sometimes the event
may occur more than once for an individual, e.g. a carcinogenicity experiment on the times to the
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development of mammary tumors for rats [11]. Besides, we may be interested in more than one
type of events. For example, we may consider different causes of death as different types of events
[34]. We will discuss these extension under the counting process formulation.
1.3 Counting Process and Martingales
In the last several decades, the theoretical foundation for survival and event history analysis has
been connected to the study of counting process and martingale theory [14, 10].
1.3.1 Martingale Basics
Doob-Meyer Decomposition Theorem is one of the most important theorems of martingale appli-
cation in counting process. The following version is from Theorem 2.2.3 in [10].
Theorem 1.1 (Doob-Meyer Decomposition) Let 𝑁 = {𝑁 (𝑡); 𝑡 ≥ 0} be a nonnegative right-
continuous F𝑡-local submartingale with localizing sequence {𝜏𝑛}, where {F𝑡 ; 𝑡 ≥ 0} is a right-
continuous filtration. Then there exists a unique increasing right-continuous predictable process
𝐴 such that 𝐴(0) = 0 a.s., 𝑃𝑟 (𝐴(𝑡) < ∞) = 1 for all 𝑡 > 0 and 𝑁 − 𝐴 is a right-continuous local
martingale. At each 𝑡, 𝐴(𝑡) may be taken as the 𝑎.𝑠. lim𝑛→∞ 𝐴𝑛 (𝑡), where 𝐴𝑛 is the compensator
of the stopped submartingale 𝑁 (· ∧ 𝜏𝑛).
Theorem 1.1 implies that any local submartingale 𝑁 can be decomposed as a local martingale
and a predictable increasing process.





Actually, the continuous compensator is frequently used in applications based on the following
theorem, from Theorem 2.5.1 in [10].
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Theorem 1.2 Let 𝑁 be a counting process on [0,∞) with E𝑁 (𝑡) < ∞ for all 𝑡 ≥ 0, and let 𝐴
denote its compensator. Assume that almost all paths of 𝐴 are continuous, and that E𝑀2(𝑡) < ∞
for all 𝑡, where 𝑀 = 𝑁 − 𝐴. Then the predictable variation process < 𝑀, 𝑀 >= 𝐴, that is 𝑀2 − 𝐴
is a right-continuous martingale.
1.3.2 Counting Process
A counting process is a stochastic process {𝑁 (𝑡); 𝑡 ≥ 0} with 𝑁 (0) = 0 and 𝑁 (𝑡) < ∞ a.s., and
whose paths are with probability one right-continuous, piecewise constant, and have only jump
discontinuities, with jumps of size +1. Suppose it is adapted to a 𝜎−filtration {F𝑡 ; 𝑡 ≥ 0}. The
intensity 𝜆(𝑡 |F𝑡) of a counting process is the rate of change in its predictable part, which is defined
as




E(𝑁 (𝑡 + 𝑑𝑡) − 𝑁 (𝑡) |F𝑡).
From the Doob-Meyer decomposition, there exists a unique predictable process 𝐴 such that
𝑁 − 𝐴 is a martingale. Therefore, we have
E(𝑁 (𝑡 + 𝑑𝑡) − 𝑁 (𝑡) |F𝑡) = E(𝐴(𝑡 + 𝑑𝑡) − 𝐴(𝑡) |F𝑡) = 𝑑𝐴(𝑡),
since 𝐴 is predictable. From this equation, we can see that 𝑑𝐴(𝑡) is the rate of change for 𝑁





for some random function 𝑙, we can model 𝑙 (𝑠) instead.
In survival analysis, with survival time 𝑇 , 𝑁 (𝑡) = 1 if 𝑡 ≥ 𝑇 and 𝑁 (𝑡) = 0, otherwise. It can be
shown that the process given by 𝑀 (𝑡) := 𝑁 (𝑡) −
∫ 𝑡
0 𝑌 (𝑢)𝜆(𝑢)𝑑𝑢 is a martingale with respect to
F𝑡 = 𝜎(𝑁 (𝑠), 𝑌 (𝑠); 0 ≤ 𝑠 ≤ 𝑡),
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provided independence censoring assumption.
By the uniqueness of Doob-Meyer decomposition, we can conclude that 𝑙 (𝑠) is like the in-
tensity 𝑌 (𝑠)𝜆(𝑠). Therefore, we also call process 𝐴 and 𝑙 as cumulative intensity function and







This provide an interpretation for the approach that models the compensator directly.
1.3.3 Poisson Process
The Poisson process is a simple and widely used counting process model for counting data over
time. Let 𝑁 (𝑡) be a Poisson Process adopted by filtration F𝑡 and cumulative intensity function
𝐴(𝑡). The 𝑁 (𝑡) satisfies the following two properties:
a 𝑁 (𝑡) − 𝑁 (𝑠) ∼ Poisson (𝐴(𝑡) − 𝐴(𝑠)) for 0 ≤ 𝑠 < 𝑡.
b 𝑁 (𝑡1) − 𝑁 (𝑠1) and 𝑁 (𝑡2) − 𝑁 (𝑠2) are independent if (𝑠1, 𝑡1] ∩ (𝑠2, 𝑡2] = ∅
If 𝐴(𝑡) is absolute continuous, there exists some random function 𝑙 (𝑠) such that 𝐴(𝑡) =
∫ 𝑡
0 𝑙 (𝑠)𝑑𝑠.
When 𝑙 (𝑡) is independent of time, the process is called homogeneous. Otherwise, it’s called in-
homogeneous. Actually, for an inhomogeneous Poisson process 𝑁 (𝑡) with 𝐴(𝑡), we can define a
new process {𝑁∗(𝑠), 𝑠 ≥ 0} by 𝑁∗(𝑠) = 𝑁 (𝐴−1(𝑠)). Then the new defined {𝑁∗(𝑠), 𝑠 ≥ 0} is a
homogeneous Poisson process with 𝑙 (𝑠) = 1.
1.3.4 Recurrent Events
Survival analysis often deals with a single event during observation period in the most cases, while
there are still more complicated situations in real world problems. Sometimes the event may occur
more than once for an individual, e.g. a carcinogenicity experiment on the times to the development
of mammary tumors for rats [11]. We call such case as recurrent events. More details and examples
are in [4].
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Instead of only one random variable 𝑇 , we consider more than one event time within an indi-
vidual. Let 𝑛 be the total number of events detected in an individual and {𝑡 𝑗 : 𝑗 = 1, · · · , 𝑛} be a
collection of times at which events occur over the time interval [𝑎, 𝑏]. We can model such data by
counting process 𝑁𝑖 (𝑡), the number of events occurring in [0, 𝑡] for individual 𝑖.
To reach the likelihood of recurrent events, we consider a partition 𝑎 = 𝑢0 < 𝑢1 < · · · <
𝑢𝑀 = 𝑏 of the interval [𝑎, 𝑏]. Each subinterval [𝑢𝑖, 𝑢𝑖+1) only contains at most one event and
{𝑡1, · · · , 𝑡𝑛} ⊆ {𝑢0, · · · , 𝑢𝑀}. Then














𝑃(Δ𝑁 (𝑢𝑖) = 1|F𝑡𝑖 )
∏
𝑖:𝑢𝑖∉{𝑡1,··· ,𝑡𝑛}
𝑃(Δ𝑁 (𝑢𝑖) = 0|F𝑢𝑖 )1−Δ𝑁 (𝑢𝑖) ,
(1.3)
where Δ𝑁 (𝑢𝑖) = 𝑁 (𝑢𝑖+1) − 𝑁 (𝑢𝑖) is the number of events in [𝑢𝑖, 𝑢𝑖+1). Recall the assumption that
the events cannot occur simultaneously, we have
𝑃(Δ𝑁 (𝑢𝑖) = 1|F𝑢𝑖 ) = 𝜆(𝑢𝑖 |F𝑢𝑖 )Δ𝑢𝑖 + 𝑜(Δ𝑢𝑖),
𝑃(Δ𝑁 (𝑢𝑖) = 0|F𝑢𝑖 ) = 1 − 𝜆(𝑢𝑖 |F𝑢𝑖 )Δ𝑢𝑖 + 𝑜(Δ𝑢𝑖).








1 − 𝜆(𝑢𝑖 |F𝑢𝑖 )Δ𝑢𝑖 + 𝑜(Δ𝑢𝑖)
]
.
Divide the above expression by
∏







1 − 𝜆(𝑢𝑖 |F𝑢𝑖 )Δ𝑢𝑖 + 𝑜(Δ𝑢𝑖)
]
[1 + 𝑜(1)] .
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Let 𝑀 → ∞ such that max𝑖 Δ𝑢𝑖 → 0, we have the likelihood
𝑛∏
𝑗=1








See also [1] for more general and rigorous derivations of the likelihood.
1.3.5 Multitype Events
There are sometimes more than one event types in real world problems. Each event type corre-
sponds to a counting process which jointly a multivariate counting process. Formally, a 𝐽−variate
process {𝑁1, · · · , 𝑁𝐽} is called a multivariate counting process if each 𝑁 𝑗 , 𝑗 = 1, · · · , 𝐽 is a count-
ing process adapted to the common filtration {F𝑡} and no two component process jump at the same
time. Like Theorem 1.2, we also have a multivariate form of continuous compensator theorem, as
Theorem 2.5.2 in [10].
Theorem 1.3 Let {𝑁1, · · · , 𝑁𝐽} be a multivariate counting process and for 𝑗 = 1, · · · , 𝐽, let 𝐴 𝑗
be the compensator of 𝑁 𝑗 . Assume that each 𝐴 𝑗 is a continuous process. Then
• < 𝑀 𝑗 , 𝑀 𝑗 >= 𝐴 𝑗 , that is 𝐴 𝑗 is the unique predictable, right-continuous, increasing process
with 𝐴 𝑗 (0) = 0 a.s and 𝐴 𝑗 (𝑡) < ∞ a.s. for any 𝑡, such that 𝑀2𝑗 − 𝐴 𝑗 is a local martingale.
• If 𝑖 ≠ 𝑗 , < 𝑀𝑖, 𝑀 𝑗 > (𝑡) = 0 a.s., that is , 𝑀𝑖𝑀 𝑗 is a local martingale.
We consider the likelihood for such multitype recurrent events of a 𝐽−variate process 𝑵(𝑡) =
{𝑁1, · · · , 𝑁𝐽}. Let F𝑡 denote the filtration at time 𝑡, which should be commonly adapted to all
components of the counting process. The intensity for each component is defined similar as before:




E(𝑁 𝑗 (𝑡 + 𝑑𝑡) − 𝑁 𝑗 (𝑡) |F𝑡).
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Like recurrent events, we assume that at most one event can occur at time 𝑡, with
𝑃(Δ𝑁 𝑗 (𝑡) = 1|F𝑡) = 𝜆 𝑗 (𝑡 |F𝑡)Δ𝑡 + 𝑜(Δ𝑡),
𝑃(Δ𝑵(𝑡) = 0|F𝑡) = 1 −
𝐽∑
𝑗=1





Δ𝑁 𝑗 (𝑡) ≥ 2|F𝑡ª®¬ = 𝑜(Δ𝑡).
Let 𝑡 𝑗 𝑘 , 𝑘 = 1, · · · , 𝑛 𝑗 denote the event times of type 𝑗 over [𝑎, 𝑏] for 𝑗 = 1, · · · , 𝐽. Similarly,
we consider a partition 𝑎 = 𝑢0 < 𝑢1 < · · · < 𝑢𝑀 = 𝑏 of [𝑎, 𝑏], where each interval [𝑢𝑖, 𝑢𝑖+1)
contains at most one event time in 𝑇 = {𝑡 𝑗 𝑘 , 𝑘 = 1, · · · , 𝑛 𝑗 , 𝑗 = 1, · · · , 𝐽} and 𝑇 ⊆ {𝑢0, · · · , 𝑢𝑀}.
Then




































𝜆 𝑗 (𝑢𝑖 |F𝑢𝑖 )Δ𝑢𝑖 + 𝑜(Δ𝑢𝑖)
 .
(1.5)




𝑘=1 Δ𝑡 𝑗 𝑘 and taking the limit as 𝑀 → ∞ such that












𝜆 𝑗 (𝑢 |F𝑢)𝑑𝑢ª®¬ .
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𝜆 𝑗 (𝑢 |F𝑢)𝑑𝑢
)]
.
We can find that each intensity function 𝜆 𝑗 is functionally independent. If the intensities do not
share the same parameters, the estimation can be performed separately by maximizing likelihood.
1.4 Regression Models
1.4.1 Covariates
In parametric and semiparametric model, we are interested in estimating if some features can affect
survival times or rate of change in event occurrence. In this way, we often consider incorporating
covariates in regression models, e.g. cox proportional hazards model. The covariates include fixed
covariates and time-varying covariates.
• Fixed covariates are independent of time, e.g. age in a short time, gender and ethnic.
• Time-varying covariates can be external and internal.
– External covariates is independent of the recurrent event process of interest. Examples
are individuals’ external measurements at different time or age in a long time period.
– Internal covariates often depend on the past history. Examples are indicators whether
one experienced the event before time 𝑡 or the total number of events one experienced.
More details and examples are in Chapter 6 in [19].
1.4.2 Self Controlled Case Series Model
The self-controlled case series (SCCS) method is based on Poisson regression to measure the causal
association between adverse events and drug exposures in postmarketing surveillance. Compared
with other regression methods, the SCCS method has two main features: (1) it only uses individuals
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with at least one event for analysis and, (2) each individual serves as his/her own control, thus
requiring each individual to have different exposure patterns [7, 8, 30]. Let 𝑖 denote the individual
index, 𝑑 denote the day index and 𝑥𝑖𝑑 be the covariates for individual 𝑖 at day 𝑑. Then, the number
of events 𝑦𝑖𝑑 follows
𝑦𝑖𝑑 |𝑥𝑖𝑑 , 𝜙𝑖 ∼ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑒𝜙𝑖+𝛽
𝑇𝑥𝑖𝑑 ).
To allow individual-level heterogeneity, individual 𝑖 is assumed to have an individual baseline
intensity 𝑒𝜙𝑖 . The SCCS method requires two assumptions:
1. Events at different days are conditionally independent given covariates and 𝜙𝑖.
2. Events are conditionally independent with future covariates given the current covariates.
With the above assumptions, the likelihood in individual 𝑖 is
𝐿𝑖 (𝒚𝑖 |𝒙𝑖, 𝜙𝑖) = 𝑃(𝑦𝑖1, · · · , 𝑦𝑖𝜏𝑖 |𝑥𝑖1, · · · , 𝑥𝑖𝜏𝑖 , 𝜙𝑖) =
𝜏𝑖∏
𝑑=1
𝑃(𝑦𝑖𝑑 |𝑥𝑖𝑑 , 𝜙𝑖).
Actually, we are interested in 𝛽 since it determines the relationship between events and covari-
ates, whereas the individual parameter 𝜙𝑖 gives no information and can be treated as a nuisance
parameter. With the Fisher-Nyeman Factorization Theorem, we can show that the observed num-
ber of events 𝑛𝑖 =
∑𝜏𝑖
𝑑=1 𝑦𝑖𝑑 is sufficient for the nuisance parameter 𝜙𝑖. This implies that we can use
the conditional likelihood in which 𝜙𝑖 is removed from the likelihood expression:










Estimation can be obtained by maximizing the conditional log-likelihood. Actually, the as-
sumptions above are likely to be violated in real world problems. For example, if an individual
experienced a myocardial infarction, he/she may be at higher risk to encounter another myocardial
infarction in the next few days. A generalized method, the positive dependence self-controlled
case series (PD-SCCS) method [29], is proposed by adding a positive term to the baseline risk.
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The PD-SCCS allows the previous event occurrences to increase the future event risk additively
based on a continuous time SCCS model with the following definition of intensity:
𝜆𝑖 (𝑡 |𝜙𝑖, F (𝑡)) = (𝑒𝜙𝑖 + 𝛿𝑁𝑖 (𝑡−))𝑒𝛽
𝑇𝑥𝑖 (𝑡) .
Such a model specification may only work in very special situations and is not easy to be extended
to more general cases.
1.4.3 Frailty Model and Random Effect Model
In the Cox proportional hazards model, we specify the intensity of 𝑁 (𝑡) with filtration F𝑡 :
𝜆(𝑡 |F𝑡) = 𝜆0(𝑡)𝑒𝛽
𝑇𝑋 (𝑡) ,
where 𝜆0(𝑡) is an unspecified baseline intensity function. In this model setting, the occurrence
of an event is independent of any earlier events unless 𝑋 (𝑡) includes the past history. Besides,
the data from real world problems are always high-dimensional, irregular and heterogeneous. The
simple proportional intensity model is not enough in some cases. The random effect model is used
in dealing with the complexity of the data [36]:
𝜆(𝑡 |𝜉, F𝑡) = 𝜉𝜆0(𝑡)𝑒𝛽
𝑇𝑋 (𝑡) ,
where 𝜉 is a random effect following some distributions. Several asymptotic theories have been
established when 𝜉 follows a gamma distribution [22, 21]. Furthermore, a broad class of intensity
models with random effects that may accommodate nonproportional intensity is proposed [36]







where 𝛽 is the unknown regression parameters, 𝑏 is the random effects with density function
𝜓(𝑏; 𝛾), 𝑋 and 𝑍 are covariate processes associated with fixed and random effects, and 𝐺 (·)
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is a three times continuously differentiable and strictly increasing transformation function with
𝐺 (0) = 0 and 𝐺 (∞) = ∞.
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Chapter 2: A Multivariate Correlated Frailty Model for Postmarketing
Surveillance
2.1 Introduction
A primary purpose of the postmarketing surveillance is to monitor the safety of a pharmaceutical
drug or medical device after it has been released in the market. That is to say, we are interested in
identifying and estimating the association between adverse events (AEs) and drug exposures along
the time in Longitudinal Observational Databases (LODs), which contain time-to-event medical
information such as dates of diagnoses and prescription and length of drug exposure periods.
Some methods in postmarketing surveillance have been developed recently, e.g. self-controlled
case series (SCCS) method. The SCCS method [30, 29] is based on Poisson regression to measure
the causal association between adverse events and drug exposures in postmarketing surveillance.
Compared with other regression methods, the SCCS method has two main features: (1) it only
uses individuals with at least one event for analysis and, (2) each individual serves as his/her own
control, thus requiring each individual to have different exposure patterns.
Although the SCCS related methods have achieved empirical success in postmarketing surveil-
lance with the Observational Medical Outcomes Partnership (OMOP) project, these methods still
have limitation due to model design:
• Low efficiency. The SCCS analysis only includes patients with at least one adverse event
and the information from the controls is not included. In addition, each case individual needs
to have different exposure patterns.
• Limited dependence structure. The SCCS methods require conditional independence as-
sumption between multiple event occurrences. However, such an assumption is likely to
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Figure 2.1: Hidden Confounding Factors
be violated because the previous event occurrence can change the risk of future event. An
extension of the SCCS model is given by adding a positive term to the baseline event risk
[29]. This design of model may only work in very special situations and is not easy to be
extended to generalized cases.
• Failure in multivariate events. In the SCCS model setting, mathematical structure fails in
multivariate events unless each adverse event is treated as an independent model. Actually,
this is impractical in real world problems.
In this chapter, we discuss a multivariate random effect model based on event history analysis.
A central component of the proposed model is its flexible representation form to describe the ca-
sual association between multiple events and correlation structure of within-subject heterogeneity.
Event history analysis consists of statistical methods for the analysis of longitudinal data on the
occurrence and timing of events. Furthermore, the event occurrence may be high-dimensional,
irregular, and heterogeneous. Simple event history methods may not be enough to describe the na-
ture of event occurrences due to complicated hidden confounding factors or unobserved covariates
as in Figure 2.1.
To account for the heterogeneity, the unobserved covariates are included as random effect
which allows the effects of unobserved covariates on multiple events to keep the possible cor-
relation structure. The frailty model is a random effect model for time variables, where the random
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effect (the frailty) has a multiplicative effect on the intensity:
𝜆𝑖 (𝑡 |𝜃𝑖, F𝑡) = 𝜃𝑖𝑒𝛽
𝑇𝑋𝑖 ,
whereas the frailty 𝜃𝑖 follows distributional assumptions due to mathematical convenience. In
multivariate cases, the frailty can be more complex and high dimensional. We assume 𝐾 types of
event and 𝑁 individuals. For intensity at individual 𝑖 and event 𝑘 ,
𝜆𝑖𝑘 (𝑡 |𝜃𝑖𝑘 , F𝑡) = 𝜃𝑖𝑘𝑒𝛽
𝑇
𝑘 𝑋𝑖𝑘 ,
and we assume the frailty vector within the same individual 𝝓𝑖 = [𝜙𝑖1, · · · , 𝜙𝑖𝑘 ] follows some
multivariate distribution Ψ.
In univariate cases, gamma distribution is commonly used due to its compatibility with the
Poisson counting process. Actually, when the variance of gamma frailty goes to infinity, the effect
estimators of the frailty model will converge to it in the SCCS method. We leave the proof in
section 2.6 . In multivariate cases, things become more complicated. When Ψ is degenerated to
one dimension [16], we call it shared frailty model which uses one latent variable as the individual-
level heterogeneity for multiple event types. The correlated PVF frailty model [35] was proposed
in gamma structure which is a bivariate extension of the univariate PVF frailty model [17]. Some
works [20] discussed similar models but used a compound Poisson distribution for correlation
structure.
These gamma frailty models provide good views of bivariate correlation structure in event
history analysis. However, two problems prevent it to be applied in general cases. The first problem
is that bivariate gamma frailty only provides non-negative correlation due to its structure. Another
problem is that the complexity of model increase substantially when the number of event types
increases. In this chapter, we will discuss a multivariate Gaussian frailty model, which can be
easily extended to high dimension and complicated cases.
Here is the outline of this chapter. In section 2.2, we construct the multivariate correlated
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frailty model. We discuss the estimation methods for such model in section 2.3. In section 2.4, we
compare the multivariate correlated frailty model with independent frailty and shared frailty model
through simulation studies. In section 2.5, we introduce the application of our proposed model
in a EHR dataset with events of interest defined by Observational Medical Outcomes Partnership
(OMOP) project.
2.2 Model Setting
We introduce a multivariate correlated frailty model with multiple drug exposures and multiple
adverse events. We consider our model with possibly right-censored data. Let 𝑁, 𝐽, 𝐿 denote the
number of individuals, number of adverse events and number of drug exposures respectively. The
data consists of {𝑵𝑖 (𝑡),𝒀 𝑖 (𝑡), 𝑿𝑖 (𝑡) : 𝑡 ∈ [0, 𝜏𝑖], 𝑖 = 1, 2, · · · , 𝑁}. Let 𝜏𝑖 denote the length of
the observation period. 𝑵𝑖 (𝑡) = (𝑁𝑖1(𝑡), 𝑁𝑖2(𝑡), · · · , 𝑁𝑖𝐽 (𝑡))𝑇 is the occurring number of adverse
events between starting time and time 𝑡 and 𝒀 𝑖 (𝑡) = (𝑌𝑖1(𝑡), 𝑌𝑖2(𝑡), · · · , 𝑌𝑖𝐽 (𝑡))𝑇 is at risk status
defined by 𝑌𝑖 𝑗 (𝑡) = I(𝐶𝑖 𝑗 ≥ 𝑡), where 𝐶𝑖 𝑗 is the right-censoring time. Then we have intensity for
counting process 𝑁𝑖 𝑗 (𝑡)
𝜆𝑖 𝑗 (𝑡 |𝜙𝑖 𝑗 , F𝑡) = 𝑌𝑖 𝑗 (𝑡)𝜆0 𝑗 (𝑡)𝑒𝜙𝑖 𝑗+𝜷
𝑇
𝑗 𝑿𝑖 𝑗 (𝑡) .















where 𝚺 is a 𝐽 × 𝐽 positive definite matrix. The mean of this multivariate Gaussian distribution is
set to guarantee the mean of frailty 𝑒𝜙𝑖 𝑗 to be 1.
The parameters 𝜷 𝑗 is a coefficient vector for 𝑗−th adverse event and 𝑿𝑖 𝑗 (𝑡) is a covariate
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vector. If we focus on estimating the strength of the association between adverse events and drug
exposures, we can replace 𝑿𝑖 𝑗 (𝑡) with 𝑿𝑖 (𝑡) since drug exposure information is independent of
adverse event index 𝑗 . In this way, the drug index is given by 𝑙 = 1, 2, · · · , 𝐿 and the observed
drug exposure covariate is given by 𝑿𝑖 (𝑡) = (𝑋𝑖1(𝑡), 𝑋𝑖2(𝑡), · · · , 𝑋𝑖𝐿 (𝑡))𝑇 , where 𝑋𝑖𝑙 (𝑡) = 1 if the
individual 𝑖 is exposed to the drug 𝑙 at time 𝑡, and 0 otherwise.
The above model includes only drug exposures as covariates which ignores that the occurrence
of an event can affect the risk of future events. For example, if an individual experienced a myocar-
dial infarction, he may be more likely to experience another myocardial infarction in the next few
days. Such phenomenon can even exist between two different events. For example, cardiovascular
disease and chronic kidney disease are closely interrelated since disease of one organ can cause
dysfunction of the other, ultimately leading to the failure of the both organs. Actually, these prob-
lems are common in the application of postmarketing surveillance which inspires us to incorporate
the covariates with the history of adverse events, such as cumulative event numbers or indicators.
In this chapter, for simplicity, we include similar indicator covariates for adverse events as drug
exposures with intensity
𝜆𝑖 𝑗 (𝑡 |𝜙𝑖 𝑗 , F𝑡) = 𝑌𝑖 𝑗 (𝑡)𝜆 𝑗0(𝑡)𝑒𝜙𝑖 𝑗+𝜷
𝑇
𝑗 𝑿𝑖 (𝑡)+𝜼𝑇𝑗 𝒁𝑖 (𝑡) ,
where 𝒁𝑖 (𝑡) = {𝑍𝑖1(𝑡), 𝑍𝑖2(𝑡), · · · , 𝑍𝑖𝐽 (𝑡)} is a covariate vector of adverse events and 𝑍𝑖 𝑗 (𝑡) = 1 if
adverse event 𝑗 occurs before time 𝑡 and 0 otherwise.
Based on above notations and discussion, the likelihood function for parameters 𝜃 = {𝜷, 𝜼,𝚺}











𝑌𝑖 𝑗 (𝑡)𝜆 𝑗0(𝑡)𝑒𝜙𝑖 𝑗+𝜷
𝑇







𝑌𝑖 𝑗 (𝑡)𝑒𝜙𝑖 𝑗+𝜷
𝑇




If we consider Λ 𝑗0(𝑡) as absolute continuous functions, we can not reach a maximum of the
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likelihood. Thus, we restrict Λ 𝑗0(𝑡) in step functions with jumps at the observed event times
{𝑡𝑖 𝑗 𝑘 , 𝑖 = 1, 2, · · · , 𝑛; 𝑗 = 1, 2, · · · , 𝐽; 𝑘 = 1, 2, · · · , 𝑛𝑖 𝑗 } and the baseline intensity 𝜆 𝑗0(𝑡) becomes











𝑌𝑖 𝑗 (𝑡)Λ 𝑗0{𝑡}𝑒𝜙𝑖 𝑗+𝜷
𝑇







𝑌𝑖 𝑗 (𝑡)𝑒𝜙𝑖 𝑗+𝜷
𝑇




The theory about consistency and asymptotically normality is discussed in the next chapter,
where we establish a general asymptotic theory for nonparametric maximum likelihood estimation
in event history analysis with dynamic random effect.
2.3 Estimation
In the gamma frailty model, parameters estimation is mostly based on maximizing the integrated
likelihood by simple convex optimization algorithms, e.g. gradient descent method and newton’s
method. This is because the probability density function of gamma distribution and the likelihood
of Poisson process are in the same exponential family and we can integrate the likelihood (2.2) in a
closed form. However, the multivariate Gaussian distribution can not derive such closed form. The
Expectation-Maximization algorithm was discussed [36] by implementing Gaussian-quadrature
approximation for Gaussian frailty for conditional expectations numerical integration in E-step. In
this thesis, we will discuss the Bayesian approach applied in full likelihood.
The Bayesian approach for this model requires determination of the full probability model, in-
cluding the conditional survival likelihood, the distribution of the frailty and the prior distributions
of the parameters. Let 𝐷obs denote the data and R = {𝝓𝑖, 𝑖 = 1, 2, · · · , 𝑁} denote the frailty, the
full likelihood for the data and model is








The Markov Chain Monte Carlo (MCMC) method allows us to obtain a series of samples
from the targeted posterior distribution by a Markov chain. In some papers [12], adequate burn-in
periods are necessary to approximately sample from a known posterior distribution. However, the
full posterior likelihood is intractable and thus we implement Gibbs sampling algorithm which
requires condition distributions of each parameter given all other parameters.
For frailty covariance parameter 𝚺 which is positive definite, we re-parametrize the covariance
matrix by 𝛀 = 𝚺−1 to use the conjugate prior. For the prior, we use a Wishart prior which is defined
over positive definite matrix with hyperparameters of a real number 𝑎 and a positive definite matrix
𝑽𝐽×𝐽 :
𝛀 ∼ W(𝛀; 𝑎,𝑽),
𝑓 (𝛀) = |𝛀|
(𝑎−𝐽−1)/2𝑒−𝑡𝑟 (𝑽
−1𝛀)/2
2 𝐽𝑎2 |𝑽 |𝑎/2Γ𝐽 ( 𝑎2 )
.
(2.4)
Usually, we set 𝑎 = 𝐽 and 𝑽 = 𝑛−1𝚺0 where 𝚺0 is some prior guess for the covariance matrix.
There are many possible choices for baseline parameters A, e.g. piecewise linear function or
constant function. In our database, the observation period is short and there is no obvious starting
point. Thus, we assume the baseline keeps constant during the observation period for simplicity.
We use 𝛼 𝑗 to represent the baseline intensity for event type 𝑗 .
For baseline parameters 𝛼 𝑗 and relative risk parameters 𝜷 𝑗 and 𝜼 𝑗 , we use noninformative
priors on them with an independent univariate Normal prior with zero mean and large variance
𝜏𝛼, 𝜏𝛽, 𝜏𝛾, e.g. 1000:
𝛼 𝑗 ∼ N(0, 𝜏𝛼),
𝛽 𝑗 𝑙 ∼ N(0, 𝜏𝛽),
𝜂 𝑗 𝑙 ∼ N(0, 𝜏𝛾).
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× |𝛀| (𝑎−𝐽−1)/2𝑒−𝑡𝑟 (𝑽−1𝛀)/2.
(2.5)
2.4 Simulation Comparison Among Different Frailty Models
The goal of this section is to compare the performance of a variety of frailty models through
simulation studies. We simulate the data from shared frailty, independent frailty and correlated
frailty model, respectively. For each simulated data, we fit it with all three models and compare
their performance under different parameter settings.
2.4.1 True Model Being Correlated Frailty
We simulate data from correlated frailty model first. We simulate 𝑁 = 10, 000 individuals and each
of them has an observation period 𝜏 = 1, 000. We run such simulation 1, 000 times with the same
model settings to generate 1, 000 estimators. To make the results clear for comparison, we choose
𝐽 = 2 adverse events and 𝐿 = 1 drugs exposure for simplicity. We also incorporate the adverse
event indicators as covariates. Then the correlated frailty model becomes
log𝜆𝑖1(𝑡 |𝜙𝑖1, F𝑡) = 𝛼1 + 𝜙𝑖1 + 𝛽1𝑋𝑖 (𝑡) + 𝜂11𝑍𝑖1(𝑡) + 𝜂12𝑍𝑖2(𝑡),



















We generate drug exposures by exponential distribution with mean 0.001. For each drug ex-
posure, we extend it with 𝑑 = 30 days since we assume each prescription period is 30 days and
individuals are under drug exposure during the prescription period. Then 𝑋𝑖 (𝑡) is a time-varying
indicator of drug exposure. The covariate for adverse event 𝑍𝑖 𝑗 (𝑡) = 1 if adverse event 𝑗 occurs
before time 𝑡 within 30 days and 0, otherwise.










For other parameters 𝜶, 𝜌 and 𝜎1, 𝜎2, we vary them in a range of values to compare the perfor-
mance of three models in different parameter settings. The baseline parameters 𝑒𝛼1 = 𝑒𝛼2 are set
as 0.0001,0.0005 and 0.001. Based on the definition of Poisson process, these values correspond
to the expected number of events as 0.1, 0.5 and 1.0, respectively. Considering the strength of
correlation structure, we vary 𝜌 among 0.1, 0.5 and 0.9, representing from relatively uncorrelated
structure to highly positive correlated structure. For 𝜎1, 𝜎2, we fix 𝜎1 as 1.0 but vary the ratio
𝜎2/𝜎1 among 1.0, 1.5 and 2.0.
We show the estimation results of 𝛽1 and 𝜂12 in table 2.1 , 2.2 and 2.3 and the estimation results
of 𝜌 in table 2.4.
Table 2.1 shows mean square error (MSE) and median absolute deviation (MAD) for 𝛽1 when
the true model is correlated frailty model. When 𝜌 is small (𝜌 = 0.1), the correlated frailty model
and independent model give similar MSE and MAD. When the value of 𝜌 increases, the correlated
frailty model performs better than the independent frailty model. The shared frailty model is
always the worst in MSE and MAD and the error grows with increasing 𝜌 and 𝜎2/𝜎1.
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𝜂12 is the relative risk parameters of effect from adverse event 2 to adverse event 1, which may
be biased if the frailty structure is ignored. Actually, an example in section 2.6 illustrates that
when the covariate is correlated with outcome (or frailty), the independence assumption would
lead estimation bias. Table 2.2 shows mean square error (MSE) and median absolute deviation
(MAD) for 𝜂12 when the true model is correlated frailty model. The correlated frailty model has
the best performance and the lowest errors among three models for all settings. The shared frailty
model has worst performance and the estimation errors are much larger, which can be 100 times
of the error in the correlated frailty model. The performance of the independent frailty model is
better than it in the shared frailty model, but much worse than it in the correlated frailty model,
except the case with the small correlation 𝜌 and small 𝜎2/𝜎1 ratio.
Table 2.3 shows the 95% confidence interval coverage for 𝛽1 and 𝜂12 when the true model is
correlated frailty model. The 95% confidence interval coverage is the probability that true param-
eter value falls in the empirical 95% confidence intervals. When 𝜌 is at a low level (𝜌 = 0.1) or
𝜎2/𝜎1 = 1 , the independent frailty model and shared frailty model have similar performance as
the correlated frailty model. When the correlation 𝜌 and 𝜎2/𝜎1 ratio increase, the coverage for the
independent frailty model and shared frailty model both decrease, while the later one decreases
much faster. The shared frailty model has terrible performance in the case of large 𝜎2/𝜎1 and large
𝑒𝛼. With respect to 𝜂12, the shared frailty model has zero 95% coverage in all most cases, except
with large 𝜌 and 𝜎1 = 𝜎2. The independent frailty model also has terrible performance. The cov-
erage is above 68% when the correlation coefficient 𝜌 is small. When 𝜌 increases, the coverage
under independent frailty model drops sharply.
Table 2.4 shows the estimation result summary for 𝜌 when the true model is correlated frailty
model. The Bias ?̂? column shows the bias of the 𝜌 estimators over all iterations. The absolute
values of the bias are all at a low level which are less than 7.5% of the corresponding true values
and 20% of the standard errors. On average, the bias with small 𝜌 is larger than it with large 𝜌.
The 95% coverage levels are generally close to 95% and at least 90%. The last two columns gives
the proportion of times that BIC favored the correlated frailty model over the other two models.
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Actually, all the values are large than 99.2% and in most cases, the criterion can choose the true
model.
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𝜌 𝑒𝛼 (×10−3) 𝜎2/𝜎1
MSE 𝛽1 (×10−3) MAD 𝛽1 (×10−2)
Correlated Independent Shared Correlated Independent Shared
1.0 2.943 2.959 2.945 3.220 3.156 3.288
0.5 1.5 2.552 2.568 3.706 3.221 3.296 4.421
2.0 3.239 3.265 5.861 4.141 4.149 5.946
1.0 1.326 1.349 1.365 2.401 2.367 2.466
0.1 1.0 1.5 0.975 0.987 2.937 2.200 2.270 4.434
2.0 0.940 0.957 3.990 2.082 1.954 5.445
1.0 0.475 0.476 1.006 1.526 1.555 2.490
2.0 1.5 0.536 0.544 2.995 1.541 1.434 5.043
2.0 0.533 0.547 3.579 1.541 1.642 5.386
1.0 2.774 2.954 2.684 3.629 3.632 3.688
0.5 1.5 3.293 3.356 4.758 3.346 3.300 4.569
2.0 2.997 3.122 6.662 3.302 3.364 6.519
1.0 1.221 1.319 1.316 2.270 2.093 2.309
0.5 1.0 1.5 1.425 1.737 3.224 2.607 2.888 4.094
2.0 0.998 1.277 5.051 2.087 2.307 6.752
1.0 0.668 0.842 0.792 1.601 1.931 2.039
2.0 1.5 0.469 0.654 3.538 1.485 1.745 5.560
2.0 0.609 0.828 5.278 1.837 2.108 6.724
1.0 3.026 3.343 2.988 3.780 3.962 3.789
0.5 1.5 3.061 4.007 4.040 4.032 4.149 5.423
2.0 3.118 4.970 5.605 4.163 5.278 5.231
1.0 1.433 1.744 1.450 2.355 2.347 2.606
0.9 1.0 1.5 1.085 1.548 3.757 2.411 2.763 5.112
2.0 1.965 3.224 7.687 2.932 4.066 7.574
1.0 0.566 1.151 0.560 1.490 2.565 1.570
2.0 1.5 0.599 1.458 4.000 1.842 3.042 5.771
2.0 0.717 1.621 9.370 1.807 3.619 8.622
Table 2.1: MSE and MAD for 𝛽1 under correlated frailty, independent frailty and shared frailty
when true mode is correlated frailty model
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𝜌 𝑒𝛼 (×10−3) 𝜎2/𝜎1
MSE 𝜂12 (×10−2) MAD 𝜂12 (×10−1)
Correlated Independent Shared Correlated Independent Shared
1.0 2.087 2.202 39.562 0.968 1.074 6.096
0.5 1.5 2.366 2.280 211.603 1.008 0.957 14.324
2.0 2.484 3.030 478.846 1.066 1.153 21.688
1.0 0.549 0.610 39.032 0.418 0.580 6.037
0.1 1.0 1.5 0.443 0.796 181.168 0.504 0.621 13.335
2.0 0.698 1.307 411.063 0.417 0.841 20.110
1.0 0.124 0.184 36.694 0.315 0.283 6.045
2.0 1.5 0.143 0.328 154.199 0.260 0.441 12.339
2.0 0.183 0.488 348.795 0.325 0.542 18.515
1.0 1.493 6.300 12.650 0.751 2.328 3.316
0.5 1.5 1.229 13.228 91.775 0.805 3.403 9.350
2.0 1.108 21.055 268.959 0.671 4.442 16.102
1.0 0.384 3.213 11.074 0.411 1.694 3.373
0.5 1.0 1.5 0.287 6.502 82.736 0.370 2.563 9.170
2.0 0.367 12.027 225.910 0.311 3.491 14.869
1.0 0.091 1.274 12.243 0.194 1.088 3.505
2.0 1.5 0.092 3.276 73.903 0.205 1.801 8.537
2.0 0.112 4.782 189.450 0.246 2.122 13.588
1.0 1.223 13.426 1.978 0.822 3.459 0.884
0.5 1.5 0.740 33.468 25.728 0.622 5.758 4.958
2.0 0.600 54.954 120.061 0.578 7.271 10.709
1.0 0.230 6.632 0.697 0.304 2.575 0.672
0.9 1.0 1.5 0.203 15.802 24.520 0.289 3.955 4.866
2.0 0.192 28.785 109.001 0.304 5.311 10.198
1.0 0.064 2.890 0.704 0.174 1.683 0.769
2.0 1.5 0.068 7.737 24.815 0.186 2.767 4.937
2.0 0.059 13.113 106.722 0.182 3.554 10.029
Table 2.2: MSE and MAD for 𝜂12 under correlated frailty, independent frailty and shared frailty
when true mode is correlated frailty model
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𝜌 𝑒𝛼 (×10−3) 𝜎2/𝜎1
95% Coverage 𝛽1 (%) 95% Coverage 𝜂12 (%)
Correlated Independent Shared Correlated Independent Shared
1.0 93.5 93.5 91.5 94.5 94.7 0.0
0.5 1.5 92.8 92.8 88.8 95.8 92.3 0.0
2.0 91.4 91.4 79.4 93.4 84.1 0.0
1.0 92.8 92.8 91.8 93.8 93.2 0.0
0.1 1.0 1.5 99.7 100.0 74.7 96.7 84.4 0.0
2.0 98.0 98.0 65.0 93.0 80.0 0.0
1.0 95.1 98.1 86.1 98.1 87.1 0.0
2.0 1.5 93.9 93.9 38.9 95.9 75.3 0.0
2.0 95.4 95.4 34.4 97.4 68.2 0.0
1.0 94.4 94.4 96.4 94.4 50.0 15.4
0.5 1.5 91.1 87.1 86.1 95.1 14.7 0.0
2.0 90.6 85.6 80.6 94.6 3.0 0.0
1.0 92.2 93.2 94.2 94.2 19.8 0.0
0.5 1.0 1.5 94.2 88.2 74.2 96.2 1.2 0.0
2.0 97.0 86.0 53.0 95.0 0.0 0.0
1.0 93.5 88.5 89.5 93.5 7.1 0.0
2.0 1.5 97.4 85.4 32.4 96.4 0.0 0.0
2.0 93.0 83.0 23.0 95.0 0.0 0.0
1.0 90.9 87.9 86.9 92.9 10.9 82.1
0.5 1.5 93.4 85.4 81.4 94.4 0.0 0.0
2.0 96.2 83.2 78.2 97.2 0.0 0.0
1.0 91.5 85.5 85.5 92.5 0.0 73.4
0.9 1.0 1.5 99.2 84.2 76.2 95.2 0.0 0.0
2.0 86.7 77.7 49.7 94.7 0.0 0.0
1.0 92.6 83.6 85.6 94.6 0.0 6.1
2.0 1.5 97.8 78.8 38.8 93.8 0.0 0.0
2.0 91.4 77.4 10.4 97.4 0.0 0.0
Table 2.3: Coverage of 95% CIs for 𝛽1 and 𝜂12 under correlated frailty, independent frailty and
shared frailty when true mode is correlated frailty model
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𝜌 𝑒𝛼 (×10−3) 𝜎2/𝜎1 Bias ?̂?(×10−3) SE ?̂?(×10−2) 95% Coverage ?̂?(%) BIC(%)
Independent Shared
1.0 -2.092 3.365 98.2 99.2 99.9
0.5 1.5 -5.789 3.043 93.0 99.8 100.0
2.0 -6.152 3.111 95.3 100.0 100.0
1.0 1.715 2.336 97.1 99.8 99.8
0.1 1.0 1.5 -0.143 2.220 95.4 100.0 100.0
2.0 3.224 2.302 96.0 100.0 100.0
1.0 -3.254 1.766 91.0 99.4 100.0
2.0 1.5 -1.396 1.740 94.9 99.5 100.0
2.0 -2.949 1.825 94.6 100.0 100.0
1.0 -7.392 2.953 90.3 99.7 99.8
0.5 1.5 1.723 2.586 96.4 99.6 100.0
2.0 0.594 2.606 94.3 100.0 100.0
1.0 -3.720 1.987 93.2 99.9 99.8
0.5 1.0 1.5 -0.882 1.858 95.5 100.0 100.0
2.0 0.535 1.912 95.4 100.0 100.0
1.0 1.814 1.459 90.4 100.0 100.0
2.0 1.5 -0.161 1.422 94.8 99.9 100.0
2.0 2.308 1.472 98.5 100.0 100.0
1.0 -3.135 1.903 90.1 99.8 100.0
0.5 1.5 -2.926 1.507 94.6 100.0 100.0
2.0 -0.428 1.458 94.8 100.0 100.0
1.0 -0.924 1.121 97.3 100.0 100.0
0.9 1.0 1.5 0.153 0.950 96.6 100.0 100.0
2.0 0.567 0.933 92.8 100.0 100.0
1.0 -1.291 0.698 92.8 100.0 100.0
2.0 1.5 -0.072 0.625 94.5 100.0 100.0
2.0 0.430 0.625 94.9 100.0 100.0
Table 2.4: Empirical bias, variance estimates, and coverage of 95% CIs for correlation parameter
?̂? when true mode is correlated frailty model
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2.4.2 True Model Being Independent Frailty
We simulate data from independent frailty model and fit the data with three models respectively.
We use similar settings as previous with 𝑁 = 10, 000 and 𝜏 = 1, 000 and intensity is same as before
except the distribution of frailty:
log𝜆𝑖1(𝑡 |𝜙𝑖1, F ) = 𝛼1 + 𝜙𝑖1 + 𝛽1𝑋𝑖 (𝑡) + 𝜂11𝑍𝑖1(𝑡) + 𝜂12𝑍𝑖2(𝑡),
log𝜆𝑖2(𝑡 |𝜙𝑖2, F ) = 𝛼2 + 𝜙𝑖2 + 𝛽2𝑋𝑖 (𝑡) + 𝜂21𝑍𝑖1(𝑡) + 𝜂22𝑍𝑖2(𝑡),














We generate the data with the same parameters 𝜷 and 𝜼 and vary baseline parameters 𝑒𝛼1 = 𝑒𝛼2
among 0.0001,0.0005 and 0.001 and the ratio of standard deviation 𝜎2/𝜎1 among 1.0, 1.5 and 2.0.
We show the estimation results of 𝛽1 and 𝜂12 in table 2.5, 2.6 and 2.7.
Table 2.5 shows mean square error (MSE) and median absolute deviation (MAD) for 𝛽1 when
the true model is independent frailty model. The error of the correlated frailty model is really close
to the error of independent frailty model even if the later one is the true model. Except the case of
sparse baseline, the shared frailty model generally has the significantly highest errors. In the case
of sparse baseline 𝑒𝛼 = 0.0005, the shared frailty model has the lowest estimation errors even if
the ratio of standard deviation ratio 𝜎2/𝜎1 is large. This may be because in sparsity baseline, the
simulated data does not give enough information for the structure within the frailty.
Table 2.6 shows mean square error (MSE) and median absolute deviation (MAD) for 𝜂12 when
the true model is independent frailty model. The error of the correlated frailty model is really
close to the error of the independent frailty even if the later one is the true model. The estimation
error under the shared frailty model is still the worst and much higher. This gives evidence again
that the effect estimation of internal covariates can be largely affected by the assumption of frailty
structure.
34
Table 2.7 shows 95% confidence interval coverage for estimator 𝛽1 and 𝜂12. Both correlated
frailty model and independent frailty model show around 95% for the confidence interval. For
shared frailty model, the confidence interval coverage of 𝛽1 is close to 95% with small baseline
and 𝜎2/𝜎1 ratio but it drops sharply when the baseline and 𝜎2/𝜎1 ratio increase. The coverage of
𝜂12 are all zero at all cases for shared frailty model.
𝑒𝛼 (×10−3) 𝜎2/𝜎1
MSE 𝛽1 (×10−3) MAD 𝛽1 (×10−2)
Correlated Independent Shared Correlated Independent Shared
1.0 2.777 2.763 2.724 3.325 3.314 3.130
0.5 1.5 2.683 2.678 2.367 3.310 3.329 3.197
2.0 2.681 2.676 2.087 3.191 3.237 3.132
1.0 1.170 1.173 4.253 2.144 2.151 4.195
1.0 1.5 1.225 1.228 3.377 2.015 2.060 4.811
2.0 1.095 1.088 3.374 2.193 2.163 5.250
1.0 0.569 0.572 5.269 1.698 1.672 5.002
2.0 1.5 0.486 0.486 4.438 1.518 1.509 5.457
2.0 0.575 0.573 3.751 1.742 1.681 5.861
Table 2.5: MSE and MAD for 𝛽1 under correlated frailty, independent frailty and shared frailty
when true model is independent frailty model
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𝑒𝛼 (×10−3) 𝜎2/𝜎1
MSE 𝛽1 (×10−2) MAD 𝛽1 (×10−1)
Correlated Independent Shared Correlated Independent Shared
1.0 2.651 2.587 53.543 0.930 0.859 7.000
0.5 1.5 2.624 2.473 242.702 1.188 1.120 15.691
2.0 2.715 2.602 577.115 1.232 1.099 24.045
1.0 0.570 0.556 46.671 0.422 0.422 6.764
1.0 1.5 0.504 0.499 213.215 0.503 0.504 14.514
2.0 0.630 0.641 487.953 0.576 0.564 21.698
1.0 0.132 0.132 45.142 0.252 0.266 6.696
2.0 1.5 0.171 0.158 179.078 0.276 0.272 13.243
2.0 0.259 0.233 410.209 0.332 0.319 20.219
Table 2.6: MSE and MAD for 𝜂12 under correlated frailty, independent frailty and shared frailty
when true model is independent frailty model
𝑒𝛼 (×10−3) 𝜎2/𝜎1
95% Coverage 𝛽1 (%) 95% Coverage 𝜂12 (%)
Correlated Independent Shared Correlated Independent Shared
1.0 96.0 96.0 94.0 93.0 93.0 0.0
0.5 1.5 95.1 95.1 84.1 95.1 95.1 0.0
2.0 93.2 93.2 81.2 96.2 98.2 0.0
1.0 96.5 96.5 90.5 94.5 94.5 0.0
1.0 1.5 93.1 92.1 74.1 96.1 95.1 0.0
2.0 96.5 96.5 65.5 97.5 97.5 0.0
1.0 94.1 94.1 80.1 95.1 97.1 0.0
2.0 1.5 94.2 95.2 34.2 94.2 97.2 0.0
2.0 95.4 94.4 27.4 91.4 92.4 0.0
Table 2.7: Coverage of 95% CIs for 𝛽1 and 𝜂12 under correlated frailty, independent frailty and
shared frailty when true model is independent frailty model
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2.4.3 True Model Being Shared Frailty
We simulate data from shared frailty model and fit the data with three models respectively. We
use similar settings as above with 𝑁 = 10, 000 and 𝜏 = 1, 000 and the intensity is same as before
except the distribution of frailty:
log𝜆𝑖1(𝑡 |𝜙𝑖, F ) = 𝛼1 + 𝜙𝑖 + 𝛽1𝑋𝑖 (𝑡) + 𝜂11𝑍𝑖1(𝑡) + 𝜂12𝑍𝑖2(𝑡),
log𝜆𝑖2(𝑡 |𝜙𝑖, F ) = 𝛼2 + 𝜙𝑖 + 𝛽2𝑋𝑖 (𝑡) + 𝜂21𝑍𝑖1(𝑡) + 𝜂22𝑍𝑖2(𝑡),
where the frailty
𝜙𝑖 ∼ N(−𝜎2/2, 𝜎2).
We generate the data with the same parameters 𝜷 and 𝜼 and vary baseline parameters 𝑒𝛼1 = 𝑒𝛼2
among 0.0001,0.0005 and 0.001 and the frailty standard deviation 𝜎 among 1.0, 1.5 and 2.0.
We show estimation results of 𝛽1 and 𝜂12 in table 2.8, 2.9 and 2.10.
Table 2.8 shows mean square error (MSE) and median absolute deviation (MAD) for 𝛽1 when
the true model is shared frailty model. The error for the correlated frailty model is really close
to the error for the shared frailty model even if the later one is the true model. The independent
frailty model has relatively larger error in both MSE and MAD. Table 2.9 shows mean square error
(MSE) and median absolute deviation (MAD) for 𝜂12 when the true model is shared frailty model.
Similarly, the error for correlated frailty model is really close to the error for the true model and
the independent frailty model gives relatively much larger error. Table 2.10 shows 95% confidence
interval coverage for estimator 𝛽1 and 𝜂12. Both correlated frailty model and shared frailty model
show around 95% for the confidence interval, except the case with large frailty standard deviation.
For independent frailty model, the confidence interval coverage of 𝛽1 is a little lower than the




MSE 𝛽1 (×10−3) MAD 𝛽1 (×10−2)
Correlated Independent Shared Correlated Independent Shared
1.0 3.482 3.976 3.502 4.514 4.538 4.562
0.5 1.5 3.726 5.274 3.645 3.863 3.971 3.907
2.0 2.385 2.767 2.308 3.127 3.788 3.213
1.0 1.114 2.004 1.106 2.004 2.872 1.995
1.0 1.5 1.113 2.150 1.168 2.295 3.679 2.357
2.0 1.129 1.576 1.068 2.336 2.886 2.362
1.0 0.640 1.464 0.642 1.763 2.962 1.827
2.0 1.5 0.643 1.122 0.641 1.672 2.621 1.653
2.0 0.609 0.923 0.566 1.314 2.374 1.361
Table 2.8: MSE and MAD for 𝛽1 under correlated frailty, independent frailty and shared frailty
when true model is shared frailty model
𝑒𝛼 (×10−3) 𝜎
MSE 𝛽1 (×10−3) MAD 𝛽1 (×10−2)
Correlated Independent Shared Correlated Independent Shared
1.0 5.339 153.973 5.614 4.302 38.340 4.548
0.5 1.5 2.154 62.765 2.047 3.199 23.624 3.007
2.0 2.218 27.986 1.439 3.163 15.206 2.673
1.0 2.114 74.794 2.028 3.028 27.031 3.242
1.0 1.5 1.099 35.506 0.848 2.030 18.500 1.803
2.0 1.163 19.985 0.540 2.323 13.633 1.744
1.0 0.503 33.504 0.384 1.503 18.176 1.309
2.0 1.5 0.543 19.362 0.228 1.390 13.691 0.960
2.0 0.609 13.370 0.240 1.943 11.247 1.034
Table 2.9: MSE and MAD for 𝜂12 under correlated frailty, independent frailty and shared frailty
when true model is shared frailty model
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𝑒𝛼 (×10−3) 𝜎
95% Coverage 𝛽1 (%) 95% Coverage 𝜂12 (%)
Correlated Independent Shared Correlated Independent Shared
1.0 92.1 90.1 92.1 98.1 1.4 98.1
0.5 1.5 95.1 89.1 94.1 98.1 0.0 99.1
2.0 97.9 95.9 97.9 92.9 6.2 96.9
1.0 94.5 91.5 95.5 96.5 0.0 95.5
1.0 1.5 96.6 89.6 95.6 94.6 0.0 95.6
2.0 97.1 89.1 98.1 85.1 1.0 96.1
1.0 93.4 78.4 90.4 95.4 0.0 98.4
2.0 1.5 92.1 87.1 92.1 86.1 0.0 96.1
2.0 92.0 90.0 92.0 78.0 0.0 94.0
Table 2.10: Coverage of 95% CIs for 𝛽1 and 𝜂12 under correlated frailty, independent frailty and
shared frailty when true model is shared frailty model
2.5 OMOP Data Analysis for Drug-AE Pairs
2.5.1 Background
The U.S. Food and Drug Administration (FDA) has been developing a system to detect adverse
events of marketed drugs and other medical products. FDA relies on submission of spontaneous
reports in which clinicians or patients conclude that a drug may be the cause of the certain adverse
clinical events. These records or reports are submitted voluntarily from clinicians or patients and
will vary with their skills, experience, clinical history and existence of other plausible explanations.
As a result, active surveillance of medical products applied on longitudinal observational databases
(LODs) has been brought to the forefront. Observational Outcomes Medical Partnership (OMOP)
project is prompting such observational databases and developing active surveillance methods.
The OMOP project is a public-private partnership among database source owners, academic
institutions, the FDA and pharmaceutical industries and is administered by the Foundation for the
National Institutes of Health [31]. The OMOP project is initially to explore the possible methods
to make use of observational data for drug safety problems in marketed prescription drugs.
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Some articles use four databases (CCAE, MDCD, MDCR and MSLR) in table 2.11 from the
OMOP collaborators to evaluate the performance of their proposed models. In this thesis, we focus
on an electronic health record (EHR) dataset from a healthcare and insurance company and identify
adverse events and drugs with ICD-9 codes and brand names. With the database, we compare
our proposed model with some of existing methods: disproportional analysis (DP), observational
screening (OS), SCCS and MSCCS methods. Disproportional analysis is one of the most common
methods for surveillance in spontaneous report systems. The AE-drug pair is identified if the co-
occurrence is more frequently than it under independence condition [38]. Observational Screen
[25, 24] is based on screening rates, which give the number of adverse events that occur during the
drug exposure divided by the cumulative time exposed to the drug. The measure of association in
OS is the screening rate ratio, which is the ratio of the screening rate in a treatment group to it in a
control group.




CCAE Multiple private insur-
ers
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Medicare supplement MDCR Medicare supplement 4.4
Medicaid MDCD Medicaid 11.1
MarketScan Lab MSLR Multiple 1.5
Table 2.11: Four frequently used OMOP Database for analysis and inference
2.5.2 Adverse Events and Drug Exposures
The OMOP project has established a series of definitions for adverse events and drugs. The adverse
events selected by the OMOP project are angioedema, aplastic anemia, acute liver injury, bleeding,
hospitalization due to gastrointestinal (GI) ulcer, hip fracture, hospitalization, acute MI, mortality
after MI, and acute renal failure. These adverse events were chosen based on one of the following
ways:
• Included in the always expedited spontaneous adverse-event report list.
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• Appeared in a boxed warning.
• Represented by the spectrum of incidence, background rate, and time to onset, of typically
drug-related adverse events.
• Likely to be the focus of ongoing drug safety surveillance .
The OMOP project also selects 10 drugs: angiotensin converting enzyme (ACE) inhibitors,
amphotericin B, antibiotics, antiepileptics, benzodiazepines, beta blockers, bisphosphonates, tri-
cyclic antidepressants, typical antipsychotics, and warfarin. Considering adverse events and drugs,
there are in total 100 possible pairs of drugs and AEs. However, there are only 9 AE-drug pairs
classified as "positive control" and 44 AE-drug pairs classified as "negative control".
Here the "positive control" means true associations between the adverse events and drugs,
which are determined by prior published observational database research or the adverse events
listed in the label of the drugs. The "negative control" does not have such evidence. Researchers
always evaluate the performance of the analytical methods by their ability to identify these positive













































































Table 2.12: Positive control and Negative control AE-Drug pairs
2.5.3 Evaluation Metrics
We introduce the rank-based (and threshold independent) performance measures to evaluate our
proposed model and other existing methods. Rank-based performance metrics are based on re-
ceiver operating characteristic (ROC) curve. Before introducing these metrics, we need the knowl-
edge of confusion matrix which is the foundation for the ROC curve.
A confusion matrix is a table used to describe the performance of a classification model where
the true values are known. The basic terms of true positive, true negative, false positive and false
negative are defined in table 2.13. Based on these terms, we can have more definitions:
• The true positive rate (sensitivity) is defined as the number of true positive subjects over the
total number of subjects which true is positive, i.e 𝑎/(𝑎 + 𝑐).
• The false positive rate (1-specificity) is the number of false positive subjects over the total
number of subjects which true is negative, i.e 𝑏/(𝑏 + 𝑑).
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• The precision is defined by 𝑎/(𝑎 + 𝑏).
Table 2.13: Confusion Matrix
Fact is Positive Fact is Negative
Predicted as Positive True Positive (a) False Positive (b)
Predicted as Negative False Negative (c) True Negative (d)
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We use the relative risk estimators of 9 positive pairs and 44 negative pairs in model evaluation.
We treat these 𝑀 = 53 estimators as a classification problem. Let these estimators be 𝑒𝛽(1) <
𝑒𝛽(2) < · · · < 𝑒𝛽(𝑀) . With a threshold level 𝑐, we say we predict the pair with a point estimator
𝑒𝛽(𝑚) that 𝑚 > 𝑐 as a positive label and the pair with a point estimator 𝑒𝛽(𝑚) that 𝑚 ≤ 𝑐 as a negative
label. In this way, each method, with threshold level 0 ≤ 𝑐 ≤ 𝑀 , we have total 𝑀 +1 = 54 possible
prediction results. We can define the rank-based metrics based on these prediction results.
• Area Under Curve (AUC) is based on Receiver Operating Characteristic (ROC) cure, which
is plotted by sensitivity versus 1−specificity. For each threshold level 𝑐 = 0, · · · , 𝑀 , we
have a prediction result which gives a pair (𝑥𝑐, 𝑦𝑐) where 𝑥𝑐 and 𝑦𝑐 are sensitivity and
1−specificity respectively at level 𝑐. ROC curve is plotted by these points and we hope
this curve has a sharp corner close to the upper left-hand corner of the plot. This is because
a good classification model should have large sensitivity and small 1−specificity. Based on
ROC curve, we can calculate the AUC which is the integral of this curve. Larger value of
AUC gives better classification results. 𝐴𝑈𝐶 = 1 gives a perfect classification model and
𝐴𝑈𝐶 = 0.5 is a randomly guess of labels. Some works [3] suggested that AUC is a better
summary measure of classification performance than overall accuracy.
• Partial Area Under Curve (PAUC) is a possible alternative for AUC. Sometimes we only
focus on a limited range of 1− specificity because large value of 1−specificity is not useful
and practical. We want to observe the model performance under small false positives. In
this way, we define PAUC as the integral of the area up to a cut-off at a certain level of
43
1−specificity. In this thesis, we choose such cut-off as 30% so that the maximum value of
PAUC is 0.3.
• Mean Average Precision (MAP) score is defined by the average of precision at some special
threshold level {𝑐1, · · · , }. In this case, we have 9 threshold levels 𝑐1, · · · , 𝑐9. 𝑐𝑘 is defined
as the minimum index such that if we take 𝑐𝑘 as threshold level, we would have 𝑘 true
positive predictions.
• The sensitivity at a 5% false positive rate is defined as the height of the ROC curve when
𝑐 is set to make 1−specificity as 5%. The larger value means better model performance.
• Average False Positive Rate (Average FPR) is similar to MAP score. But it is defined by
the average of false positive rate at threshold level {𝑐1, · · · , 𝑐9}. Unlike other metrics, the
larger values of Average FPR corresponds to a higher proportion of false positives and worse
method performance.
2.5.4 Real Data Results
We compare the proposed multivariate correlated frailty model (MCFM) with other existing meth-
ods DP, OS, SCCS and MSCCS in terms of the ROC curve and metrics define above. Figure 2.2
and 2.3 show ROC curves and 5 metrics in an electronic health record dataset. Table 2.14 gives nu-
merical details about the values of the metrics in Figure 2.3. The term SCCS refers to simple SCCS
method which models one adverse event and one drug exposure while MSCCS refers to multiple
SCCS method which models one adverse event and multiple drug exposures. There are several
model settings for each method, including definition of drug exposure covariates and identification
of adverse events with diagnosis code. For simplicity, we use the similar parameter settings [30],
where the models are set to give the optimal AUC values. Besides, in our proposed multivari-
ate correlated frailty model (MCFM), we incorporate adverse events as indicator covariates which
equal to 1 if such adverse event occurs before and 0 otherwise.
The ROC curves in Figure 2.2 for all five methods can give us a general sense for their per-
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formances in AE-drug pair classification in the electronic health record database. The graph is a
polygonal line with two direction, up and right. Up direction means that we identify a positive pair
as positive and right direction means that we misidentify a negative pair as positive. Compared
with MCFM and MSCCS, the other three models (DP, OS, SCCS) are closer to the diagonal and
thus has smaller AUC metric values. Besides, MCFM can identify more positive associations at
lower values of 1-specificity than the other methods, which leads a smaller value of Average FPR.
The figure 2.3 shows that our proposed approach MCFM performs the best across all five
metrics in the electronic health record database. The AUC value of MCFM is around 0.84 which
is an evidence that MCFM can work relatively well in the classification problem. The MSCCS
approach has the second highest AUC value and this is because both MSCCS and MCFM include
the confounding bystander effect and incorporate multiple drug exposures, which result in better
performance in AE-drug pair classification.
For MAP Score, PAUC at 30% and AFPR, MCFM still has the best performance among all
five methods while MSCCS has the second best performance. Due to the small number of positive
pairs, the value for sensitivity at 5% only have 10 possible values ({0/9, 1/9, 2/9, · · · , 9/9}) and
even less possible values in a low 1-specificity level (e.g. we only have 2 values {1/9, 2/9} in this
column). It is difficult to base an assessment on this metric for different methods.
The above results are subject to the identification of AE-drug associations. The positive pairs
are based on labels of drugs, previous observational research and expert consensus. And the small
number of the positive pairs limits the accuracy of classification problems and model performances.
The metrics are sensitive to the definitions of these positive associations. It is necessary to have
more positive and negative controls to reach a more convincing evaluation. OMOP project is
working on investigating more possible AE-drug pairs for model evaluation and we can extend
our work in the future. Put aside the limitation, the above results gives a preliminary assessment
of the multivariate correlated frailty model in postmarketing surveillance. Compared with other
methods, the proposed model is always the best performer. Actually, adjusting for confounding
drug exposures and implementing the correlation between adverse events can improve the accuracy
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Figure 2.2: Metrics for DP, OS, SCCS, MSCCS and MCFM in the electronic health record database
to classify AE-drug pairs.
Method AUC PAUC at 30% MAP Sensitivity at 5% AFPR
DP 0.699 0.075 0.284 0.111 0.301
OS 0.689 0.086 0.318 0.111 0.311
SCCS 0.735 0.104 0.423 0.222 0.265
MSCCS 0.801 0.117 0.443 0.111 0.199
MCFM 0.838 0.143 0.538 0.222 0.162




























































2.6.1 Bayesian Sampling Algorithm
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× |𝛀| (𝑎−𝐽−1)/2𝑒−𝑡𝑟 (𝑽−1𝛀)/2.
The conditional distribution of baseline parameters 𝛼 𝑗 is
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.
The conditional distribution of drug exposure effect parameters 𝛽 𝑗 𝑙 is
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The conditional distribution of adverse event effect parameters 𝜂 𝑗 𝑗 ′ is
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𝑌𝑖 𝑗 (𝑡)𝑒𝛼 𝑗+𝜙𝑖 𝑗+𝜷
𝑇
𝑗 𝑿𝑖 (𝑡)+𝜼𝑇− 𝑗 𝑗 ′𝒁−𝑖 𝑗 ′ (𝑡)𝑑𝑡
}
.
The conditional distribution of frailty covariance parameters Ω is
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The value of 𝜙𝑖 depends on the values of the hyperparameters 𝛀, effect parameters 𝜷, 𝜼, base-
line parameters 𝜶 and all event times of individual 𝑖. So the conditional distribution of the frailty
𝝓𝑖 is














𝑌𝑖 𝑗 (𝑡)𝑒𝛼 𝑗+𝜷
𝑇
𝑗 𝑿𝑖 (𝑡)+𝜼𝑇𝑗 𝒁𝑖 (𝑡)𝑑𝑡
 .
Adaptive Rejection Metropolis Sampling (ARMS) Algorithm Except the hyperparameter Ω,
we can not sample directly from the conditional distribution of parameters 𝜷, 𝜼,𝜶 and frailty 𝝓𝑖.
Thus we use the adaptive rejection sampling [13] to generate the samples from above conditional
distributions.
Let 𝑓 (𝑥) denote the target distribution. Adaptive rejection sampling (ARS) is an improvement
of reject sampling algorithm. In reject sampling, we generate independent samples from 𝑓 (𝑥) by
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accepting samples generated from another proposal distribution 𝑔(𝑥) with some probability, where
there is a finite constant𝑚 such that𝑚𝑔(𝑥) ≥ 𝑓 (𝑥) a.s.. However, such proposal distribution 𝑔(𝑥) is
difficult to find and in most times, the value of 𝑚 is large, which means a lot of unwanted samples
will be taken before we accept a sample. Instead of fixed proposal distribution 𝑔(𝑥) in reject
sampling algorithm, adaptive reject sampling algorithm improves efficiency by incorporating into
𝑔(𝑥) with information about 𝑓 (𝑥) obtained at each iteration. That is to say, we use a piecewise
linear function for the proposal log distribution 𝑔𝑛 (𝑥) as the "envelope" warping the target log
concave distribution, where 𝑔𝑛 (𝑥) is updated with the rejected points at each iteration. Actually,
the above conditional distributions are all log concave due to the concavity of the function 𝑓 (𝑥) =
𝐴𝑥 − 𝐵𝑥2 − 𝐶𝑒𝑥 with positive values of 𝐴, 𝐵, 𝐶. This is because 𝑓 ′′(𝑥) = −2𝐵 − 𝐶𝑒𝑥 < 0.
Let 𝑆𝑛 = {𝑥𝑖; 𝑖 = 0, 1, · · · , 𝑛 + 1} denote a current set of points in ascending order, where
𝑥0 and 𝑥𝑛+1 are the possibly lower and upper limits of the domain of the target density function
𝑓 (𝑥). For 1 ≤ 𝑖 ≤ 𝑗 ≤ 𝑛, let 𝐿𝑖 𝑗 (𝑥; 𝑆𝑛) denote the straight line through points [𝑥𝑖, log 𝑓 (𝑥𝑖)] and
[𝑥 𝑗 , log 𝑓 (𝑥 𝑗 )]. For other (𝑖, 𝑗) pairs, let 𝐿01(𝑥; 𝑆𝑛) and 𝐿𝑛,𝑛+1(𝑥; 𝑆𝑛) be vertical line at 𝑥 = 𝑥1 and
𝑥 = 𝑥𝑛 respectively. Then we define a piecewise linear function ℎ𝑛 (𝑥):
ℎ𝑛 (𝑥; 𝑆𝑛) =

𝐿1,2(𝑥; 𝑆𝑛) if 𝑥 < 𝑥1,
min
[
𝐿𝑖−1,𝑖 (𝑥; 𝑆𝑛), 𝐿𝑖+1,𝑖+2(𝑥; 𝑆𝑛)
]
if 𝑥𝑖 ≤ 𝑥 < 𝑥𝑖+1, 1 ≤ 𝑖 ≤ 𝑛 − 1,
𝐿𝑛−1,𝑛 (𝑥; 𝑆𝑛) if 𝑥 ≥ 𝑥𝑛.
(2.6)
Such function ℎ𝑛 (𝑥; 𝑆𝑛) is an envelope for log 𝑓 (𝑥), i.e ℎ𝑛 (𝑥; 𝑆𝑛) ≥ log 𝑓 (𝑥) a.s., which is illus-
trated in Fig 2.4.




exp ℎ𝑛 (𝑥), (2.7)
where 𝑔𝑛 (𝑥) is a piecewise exponential distribution and can be updated in each iteration where
𝑓 (𝑥) is evaluated. We have the following algorithm for ARS:
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x1 x2 x3 x4
Figure 2.4: Adaptive rejection function ℎ4(𝑥)
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Algorithm 1: Adaptive Rejection Sampling
Result: Get a new sample 𝑋𝐴 from target density 𝑓 (𝑥).
Initialize n and 𝑆𝑛;
while 𝑋𝐴 is not accepted do
Sample 𝑋 from exp ℎ𝑛 (𝑥) and sample𝑈 from𝑈 (0, 1);
if𝑈 > 𝑓 (𝑋)/exp ℎ𝑛 (𝑋) then
Reject 𝑋;
𝑆𝑛+1 = 𝑆𝑛 ∪ {𝑋}, keep ascending order;
Continue to sample ;
else




An example when frailty and covariate are correlated
We illustrate here that when the covariates are correlated with frailty or outcomes, the effect pa-
rameter estimation can be biased under independent assumption. We use a Poisson regression
model:
𝑌𝑖 |𝜆𝑖 ∼ Poi(𝜆𝑖),
𝜆𝑖 = 𝛾𝑖 exp(𝛽0 + 𝛽𝑋𝑖).
𝑌𝑖 is the outcome with a Poisson distribution based on covariate 𝑋𝑖 and frailty 𝛾𝑖. The frailty 𝛾𝑖




1 if 𝛾𝑖 > 𝑐,
0 if 𝛾𝑖 < 𝑐.
with 𝑐 > 1. Let 𝑀0 denote the true model and 𝑀1 denote model with assumption that frailty and
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covariate are independent. We can prove that the estimation of parameter 𝛽 under 𝑀1 is biased.











𝑋𝑖 (𝑌𝑖 − 𝑒𝛽𝑋𝑖 ).







𝑋𝑖 (𝑌𝑖 − 𝑒𝛽𝑋𝑖 ) and 𝑓𝑛 (𝛽𝑛) = 0.





































as 𝑐 > 1.
Then it suffices to show that {𝛽𝑛}∞𝑛=1 does not converge to 𝛽0.
Theorem 2.1 We have functions { 𝑓𝑛}∞𝑛=1 uniformly converge to a continuous function 𝑓 and
𝑓𝑛 (𝛽𝑛) = 0 and 𝑓 (𝛽0) = 𝐶 > 0. Then {𝛽𝑛}∞𝑛=1 does not converge to 𝛽0.
Proof By uniformly convergence, ∀𝜖 > 0, ∃𝑁1,∀𝑛 > 𝑁1, sup𝑥 | 𝑓𝑛 (𝑥) − 𝑓 (𝑥) | < 𝜖 . Since 𝑓 is
continuous at 𝛽0, ∃𝜉 > 0, | 𝑓 (𝛽) − 𝑓 (𝛽0) | < 𝜖 for all 𝛽 that |𝛽 − 𝛽0 | < 𝜉. If 𝛽𝑛 converges to 𝛽0,
then ∃𝑁2,∀𝑛 > 𝑁2, |𝛽𝑛 − 𝛽0 | < 𝜉 and thus | 𝑓 (𝛽𝑛) − 𝑓 (𝛽0) | < 𝜖 .
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Choose 𝜖 = 𝐶4 and 𝑛 > max{𝑁1, 𝑁2}, we have
𝐶 = | 𝑓𝑛 (𝛽𝑛) − 𝑓 (𝛽0) | = | 𝑓𝑛 (𝛽𝑛) − 𝑓 (𝛽𝑛) + 𝑓 (𝛽𝑛) − 𝑓 (𝛽0) |





It is a contradiction so {𝛽𝑛}∞𝑛=1 does not converge to 𝛽0. 
Gamma Frailty model and SCCS method
We prove that when the density function of frailty satisfies some conditions, the estimators of
frailty model would converge to the estimators of the SCCS method.
Lemma 2.1 If { 𝑓𝑛} and {𝑔𝑛} converge uniformly on a set 𝐸 , then { 𝑓𝑛 + 𝑔𝑛} converges uniformly
on 𝐸 . If, in addition, { 𝑓𝑛} and {𝑔𝑛} are sequences of bounded functions, then { 𝑓𝑛𝑔𝑛} converge
uniformly on 𝐸 .
Lemma 2.2 If { 𝑓𝑛} converge uniformly to 𝑓 on a set 𝐸 . Let 𝛽𝑛 be unique root of 𝑓𝑛 and 𝛽 be
unique root of 𝑓 . If 𝑓 is a continuous and strict monotone function, we have
𝛽𝑛 → 𝛽.
Proof If not, then ∃𝜖 , for all 𝑁 > 0, ∃𝑛 > 𝑁 such that |𝛽𝑛 − 𝛽 | > 𝜖 . Let 𝜂 = inf |𝑥−𝛽 |>𝜖 | 𝑓 (𝑥) −
𝑓 (𝛽) | > 0. Since { 𝑓𝑛} converge uniformly to 𝑓 , then there exists 𝑁 such that | 𝑓𝑛 (𝛽𝑛) − 𝑓 (𝛽𝑛) | < 𝜂2 .
Then we have
0 = | 𝑓𝑛 (𝛽𝑛) − 𝑓 (𝛽) |





This is a contradiction and we get 𝛽𝑛 → 𝛽. 
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Theorem 2.2 Let 𝛽(𝜃, 𝐷, 𝑋) be the maximum likelihood estimator of the following frailty model:
𝜆𝑖 (𝑡 |𝛾𝑖, F(𝑡)) = 𝛾𝑖𝑒𝛽𝑥𝑖 (𝑡) ,
where 𝛾𝑖 is a frailty with probability density function 𝑓 (·|𝜃) with mean 1 and variance 𝜃. We use
𝐷 and 𝑋 denote the observed data and covariates.
Let 𝛽∗(𝐷, 𝑋) be the maximum conditional likelihood estimator of SCCS model:
𝜆𝑖 (𝑡 |𝜙𝑖, F (𝑡)) = 𝑒𝜙𝑖+𝛽𝑥𝑖 (𝑡) ,
where 𝜙𝑖 is a constant individual baseline.
With the following conditions:
• 𝛽 ∈ B, a compact set ,













𝛽(𝜃, 𝐷, 𝑋) → 𝛽∗(𝐷, 𝑋).
Proof The likelihood function for frailty model is




























𝑥𝑖 (𝑡𝑖 𝑗 ) −
𝑁∑
𝑖=1
𝛾𝑖 (𝑒𝛽𝑇𝑖1 + 𝑇𝑖2)ª®¬ ×
𝑁∏
𝑖=1
𝑓 (𝛾𝑖 |𝜃)𝑑𝛾𝑖 .
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𝑥𝑖 (𝑡𝑖 𝑗 ) −
𝑁∑
𝑖=1


























𝑥𝑖 (𝑡𝑖 𝑗 ) −
𝑁∑
𝑖=1





















𝑥𝑖 (𝑡𝑖 𝑗 ) −
𝑁∑
𝑖=1





































−𝛾𝑖 (𝑒𝛽𝑇𝑖1 + 𝑇𝑖2)
)




−𝛾𝑖 (𝑒𝛽𝑇𝑖1 + 𝑇𝑖2)
)
× 𝑓 (𝛾𝑖 |𝜃)𝑑𝛾𝑖
.
(2.8)
The density function of gamma distribution is











Then equation (2.8) becomes





















































































𝑒𝛽𝑇𝑖1 + 𝑇𝑖2 + 1𝜃
.




converges uniformly to 𝑛𝑖
𝑒𝛽𝑇𝑖1+𝑇𝑖2 as
𝜃 → ∞. And then,
lim
𝜃→∞
𝑔𝜃 (𝛽) = 𝑔(𝛽) Uniformly,
where













We come to the maximum condition likelihood estimator 𝛽∗ of the SCCS method and the
conditional log likelihood is














































This can lead to 𝑔(𝛽∗) = 0. By Lemma 2.2, we can conclude that
lim
𝜃→∞
𝛽(𝜃, 𝐷, 𝑋) → 𝛽∗(𝐷, 𝑋).

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Chapter 3: Theoretical Results for Generalized Random Effect Model in
Multivariate Counting Processes
3.1 Introduction
In chapter 2, the multivariate correlated frailty help explain the heterogeneity in LODs and con-
struct correlation structure between multiple adverse events. Besides, the frailty, also called ran-
dom effect, can be dynamic along the process of event occurrences. This design is motivated by
the clinical settings in postmarketing surveillance. The random effect can be treated as hidden
confounding factors which affect the risk of event occurrences. On the other hand, the event oc-
currences can affect these hidden confounding factors. For example, if an individual is diagnosed
as MI, he is not likely to go to the hospital for another diagnose of MI in the next few days. In
addition, if we treat drug prescription as an event and an individual is prescribed ACE Inhibitors
for 30 days, the another prescription is not likely to occur in the next 30 days. Inspired by these
ideas, we consider the dynamic random effects.
In this chapter, we propose a generalized random effect model: dynamic random effect model
for multivariate counting process. Let 𝑁, 𝐽, 𝐿1, 𝐿2 denote the number of individuals, event types of
interest, fix effect covariates and random effect covariates. The data consist of {𝑵𝑖 (𝑡),𝒀 𝑖 (𝑡), 𝑿𝑖 (𝑡),
𝒁𝑖 (𝑡) : 𝑡 ∈ [0, 𝜏𝑖], 𝑖 = 1, 2, · · · , 𝑁}. Let 𝜏 denote the length of observation period. 𝑵𝑖 (𝑡) =
(𝑁𝑖1(𝑡), 𝑁𝑖2(𝑡), · · · , 𝑁𝑖𝐽 (𝑡))𝑇 is the occurring number of events at time 𝑡 and𝒀 𝑖 (𝑡) = (𝑌𝑖1(𝑡), 𝑌𝑖2(𝑡),
· · · , 𝑌𝑖𝐽 (𝑡))𝑇 is at risk status defined by 𝑌𝑖 𝑗 (𝑡) = I(𝐶𝑖 𝑗 ≥ 𝑡), where 𝐶𝑖 𝑗 is the right-censoring time.
Then we have intensity for counting process 𝑁𝑖 𝑗 (𝑡)
𝜆𝑖 𝑗 (𝑡 |𝜙𝑖 𝑗 , F𝑡) = 𝑌𝑖 𝑗 (𝑡)𝜆0 𝑗 (𝑡)𝑒𝜷
𝑇
𝑗 𝑿𝑖 𝑗 (𝑡)+𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑡)𝜙𝑖 𝑗 ,
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where the random effect 𝝓𝑖 = (𝜙𝑖1, 𝜙𝑖2, · · · , 𝜙𝑖𝐽 (𝑡))𝑇 follows a 𝐽 dimensional Gaussian distribution.
The covariate vector 𝑿𝑖 𝑗 (𝑡) ∈ R𝐿1×1 includes both interval and external covariates. It can be
age, gender, drug exposures and functions of previous event history. The random effect covariate
vector 𝒁𝑖 𝑗 (𝑡) ∈ R𝐿2×1 denotes the change of random effect with respect to time 𝑡. To guarantee the
identifiability property, additional assumptions on 𝜼 and 𝒁𝑖 𝑗 (𝑡) are necessary.
Based on above notations and discussion, the likelihood function for parameters 𝜃 = {𝜷, 𝜼,𝚺}











𝑌𝑖 𝑗 (𝑡)𝜆 𝑗0(𝑡)𝑒𝜷
𝑇













If we consider Λ 𝑗0(𝑡) as absolute continuous functions, we can not reach a maximum of the
likelihood. Thus, we restrict Λ 𝑗0(𝑡) in step functions with jumps at the observed event times
{𝑡𝑖 𝑗 𝑘 , 𝑖 = 1, 2, · · · , 𝑛; 𝑗 = 1, 2, · · · , 𝐽; 𝑘 = 1, 2, · · · , 𝑛𝑖 𝑗 } and the baseline intensity 𝜆 𝑗0(𝑡) becomes











𝑌𝑖 𝑗 (𝑡)Λ 𝑗0{𝑡}𝑒𝜷
𝑇














In this section, we develop a series of asymptotic theories under some regularity conditions. Ac-
tually, the nonparametric maximum likelihood estimators are shown to be identifiable, consistent
and asymptotic normal with covariance matrix that can be consistently estimated by the inverse
information matrix. Letting
(
𝜃0,A0 = {Λ0,10,Λ0,20, · · · ,Λ0,𝐽0}
)
be the true value of (𝜃,A), we
impose the following conditions on the model and data structures.
(A 1) The true value 𝜃0 lies in the interior of a compact set Θ and the true functions Λ0, 𝑗0 are
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continuously differentiable in [0, 𝜏] with Λ′0, 𝑗0(𝑡) > 0, 𝑗 = 1, 2, · · · , 𝐽.
(A 2) 𝑿𝑖 𝑗 (𝑡), 𝒁𝑖 𝑗 (𝑡) are almost surely bounded and left-continuous and have bounded left-derivatives
and right-derivatives in [0, 𝜏].
(A 3) With probability one, P(∪ 𝑗 {𝐶𝑖 𝑗 ≥ 𝜏}|𝑿𝑖 𝑗 , 𝒁𝑖 𝑗 ) > 𝛿0 > 0. This guarantees that there is a
positive expectation of number of events to be observed before the individual is censored.
(A 4) If there exists a vector 𝜉 and a deterministic function ℎ(𝑡) such that ℎ(𝑡)+𝜉𝑇𝑿𝑖 (𝑡) = 0 almost
surely, then we have ℎ(𝑡) = 0 and 𝜉 = 0. For each 𝑗 , 𝑙 = 1, · · · , 𝐽, if there exists a matrix 𝐵
such that 𝑍𝑇𝑗 (𝑡)𝐵𝑍𝑙 (𝑠) = 0 almost surely, then 𝐵 = 0. This guarantees the identifiability of
the model.
(A 5) There exists 𝐽 non-zero numbers {𝑟 𝑗 }𝐽𝑗=1 such that 𝜂 𝑗1 = 𝑟 𝑗 for 𝑗 = 1, · · · , 𝐽.
Actually, conditions (A1) and (A2) are standard assumptions of regression models in event
history analysis. Condition (A3) shows that there exists some events at risk for each individual
during the observational period, which is a standard assumption on the analysis of censored data.
The identifiability can be derived from condition (A4) and (A5). In particular, condition (A5) is
necessary when the covariance matrix in random effect is unrestricted.
We first give the identifiability of the model.
Theorem 3.1 (Identifiability) Under assumptions (A1)-(A4), the model is identifiable. That is, if
𝐿 (𝜃,A;𝐷) = 𝐿 (𝜃′,A′;𝐷), (3.3)
for all possible 𝐷 = {𝑋 (𝑡), 𝑍 (𝑡), 𝑌 𝑗 (𝑡), 𝑁 𝑗 (𝑡), 𝑗 = 1, 2, · · · , 𝐽; 𝑡 ∈ [0, 𝜏]}, then (𝜃,A) = (𝜃′,A′).









𝜆𝑖 𝑗 (𝑡 |𝜃,A, 𝜙)𝑑𝑁𝑖 𝑗 𝑒−
∫ 𝜏
0 𝜆𝑖 𝑗 (𝑠 |𝜃,A,𝜙)𝑑𝑠
 𝜓(𝜙;Σ)𝑑𝜙.
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𝜆𝑖 𝑗 (𝑡 𝑗 𝑘 |𝜃,A, 𝜙)
𝑚+𝑚′∏
𝑘=𝑚+1
𝜆𝑖 𝑗 (𝑡 𝑗 𝑘 |𝜃,A, 𝜙)𝑒−
∫ 𝜏
0 𝜆𝑖 𝑗 (𝑠 |𝜃,A,𝜙)𝑑𝑠
 𝜓(𝜙;Σ)𝑑𝜙.
With ideas of Taylor’s series of exponential function, we integrate 𝑡 𝑗1, · · · , 𝑡 𝑗𝑚 for 0 to 𝑡 𝑗 and






𝑚′! and sum over














0 𝜆 𝑗 (𝑠 |𝜃
′,A ′,𝜙′)𝑑𝑠𝜓(𝜙′;Σ′)𝑑𝜙′.
This holds for arbitrary 𝑠 𝑗 and 𝑡 𝑗 , then by the property of characteristic functions,{
𝜆 𝑗 (𝑠 𝑗 |𝜃,A, 𝜙)
}𝐽
𝑗=1 has the same distribution as
{
𝜆 𝑗 (𝑠 𝑗 |𝜃′,A′, 𝜙′)
}𝐽
𝑗=1 where 𝜙 ∼ 𝑁 (0, Σ) and
𝜙′ ∼ 𝑁 (0, Σ′). We take log operation and mean operation on both sides, we have
log𝜆 𝑗0(𝑠 𝑗 ) + 𝛽𝑇𝑗 𝑋 𝑗 (𝑠 𝑗 ) = log𝜆′𝑗0(𝑠 𝑗 ) + 𝛽′𝑇𝑗 𝑋 𝑗 (𝑠 𝑗 ).
By condition (A4), we have 𝜆 𝑗0 = 𝜆′𝑗0 and 𝛽 𝑗 = 𝛽
′
𝑗 . Subtracting from the above equation, the
























be elements of Σ′. Considering the co-
variance, for each 𝑗 , 𝑙 = 1, · · · , 𝐽, we have
𝑍𝑇𝑗 (𝑠 𝑗 )𝜂 𝑗Σ 𝑗 𝑙𝜂𝑇𝑙 𝑍𝑙 (𝑠𝑙) = 𝑍𝑇𝑗 (𝑠 𝑗 )𝜂′𝑗Σ 𝑗 𝑙 ′𝜂′𝑇𝑙 𝑍𝑙 (𝑠𝑙)
=⇒ 𝑍𝑇𝑗 (𝑠 𝑗 )
(
𝜂 𝑗Σ 𝑗 𝑙𝜂
𝑇
𝑙 − 𝜂′𝑗Σ′𝑗 𝑙𝜂′𝑇𝑙
)
𝑍𝑙 (𝑠𝑙) = 0.
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Based on condition (A4), we have 𝜂 𝑗Σ 𝑗 𝑙𝜂𝑇𝑙 − 𝜂′𝑗Σ′𝑗 𝑙𝜂′𝑇𝑙 = 0. Recall condition (A5), we have
non-zero numbers 𝑟 𝑗 such that 𝜂 𝑗1 = 𝜂′𝑗1 = 𝑟 𝑗 . This leads to 𝑟 𝑗𝑟𝑙Σ 𝑗 𝑙 = 𝑟 𝑗𝑟𝑙Σ
′
𝑗 𝑙 and 𝚺 = 𝚺
′. For




𝑙 . Consider the first row on both sides, we have
(






𝑙1, · · · , 𝜂′𝑗1𝜂′𝑙𝐽
)
,
which results in 𝜼𝑙 = 𝜼
′
𝑙 . 
The identifiability property is the foundation of model estimation and extremely important in
random effect model. The theorems about consistency and asymptotic property are based on the
results in [37]. We need to show conditions (A1)-(A5) are sufficient for conditions (C1)-(C8) in
[37].
There are some notations we need to mention first:
• 𝛾 𝑗 = (𝜷 𝑗 , 𝜼 𝑗 ).
• 𝑂𝑖 denotes the observed data of individual 𝑖.
• We rewrite the likelihood








Λ 𝑗0{𝑡}𝑌𝑖 𝑗 (𝑡)𝑑𝑁𝑖 𝑗 (𝑡)
 Ψ(𝑂𝑖; 𝜽 ,A),





Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)𝜓(𝜙𝑖;𝚺)𝑑𝜙𝑖,






𝑗 𝑿𝑖 𝑗 (𝑡)+𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑡)𝜙𝑖 𝑗
}𝑑𝑁𝑖 𝑗 (𝑡)
𝑒−𝑞𝑖 𝑗 (𝜏) ,





𝑗 𝑿𝑖 𝑗 (𝑠)+𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑠)𝜙𝑖 𝑗𝑑Λ 𝑗0(𝑠).
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• We define derivatives of Ψ with respect to 𝜽 and Λ 𝑗0.
– ¤Ψ𝜽 denotes the derivative of Ψ with respect to 𝜽 .
– 𝐻 𝑗 belongs to the function set where Λ 𝑗0 + 𝜖𝐻 𝑗 is increasing with bounded total varia-
tion. Let ¤Ψ 𝑗 denote the derivative of Ψ along the path (Λ 𝑗0 + 𝜖𝐻 𝑗 ) with formula
¤Ψ 𝑗 [𝐻 𝑗 ] = lim
𝜖→0
Ψ(𝑂𝑖; 𝜽 ,A + (0, · · · , 𝜖𝐻 𝑗 , · · · , 0)) − Ψ(𝑂𝑖; 𝜽 ,A)
𝜖
.
The following eight propositions are the conditions (C1)-(C8) listed in [37] with our settings
and notations. We need to prove that these conditions can be reached based on our conditions
(A1)-(A5).
Proposition 3.1 The true value 𝜃0 lies in the interior of a compact set Θ and the true functions
Λ0, 𝑗0 are continuously differentiable in [0, 𝜏] with Λ′0, 𝑗0(𝑡) > 0, 𝑗 = 1, 2, · · · , 𝐽.
Proof This is the same as condition (A1). 
Proposition 3.2 With probability one, 𝑃(inf𝑠∈[0,𝑡] 𝑌𝑖 𝑗 (𝑠) ≥ 1|𝑋𝑖 𝑗 , 𝑌𝑖 𝑗 ) > 𝛿0 > 0 for all 𝑡 ∈ [0, 𝜏].
Proof This can be derived directly from condition (A3). 
Proposition 3.3 There exist a constant 𝑐1 > 0 and a random variable 𝑟1(𝑂𝑖) > 0 such that
E(log 𝑟1(𝑂𝑖)) < ∞ and for any 𝜃 ∈ Θ and any finite Λ1, · · · ,Λ𝐽 ,









𝑌𝑖 𝑗 (𝑡)𝑑Λ 𝑗 (𝑡)




𝑌𝑖 𝑗 (𝑡)𝑑Λ 𝑗 (𝑡)
}−𝑐1
, (3.4)
almost surely. In addition, for any constant 𝑐2,
inf
{
Ψ(𝑂𝑖, 𝜃,A) : ‖Λ1‖𝑉 [0,𝜏] ≤ 𝑐2, · · · , ‖Λ𝐽 ‖𝑉 [0,𝜏] ≤ 𝑐2, 𝜃 ∈ Θ
}
> 𝑟2(𝑂𝑖) > 0, (3.5)
where 𝑟2(𝑂𝑖), which may depend on 𝑐2, is a finite random variable with E(| log 𝑟2(𝑂𝑖) |) < ∞ and
‖ℎ‖𝑉 [0,𝜏] is the total variation of ℎ(·) in [0, 𝜏].
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Proof Recall that





Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)𝜓(𝜙𝑖;𝚺)𝑑𝜙𝑖,






𝑗 𝑿𝑖 𝑗 (𝑡)+𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑡)𝜙𝑖 𝑗
}𝑑𝑁𝑖 𝑗 (𝑡)
𝑒−𝑞𝑖 𝑗 (𝜏) ,





𝑗 𝑿𝑖 𝑗 (𝑠)+𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑠)𝜙𝑖 𝑗𝑑Λ 𝑗0(𝑠).
Due to the boundedness of parameters 𝜷, 𝜼 and covariates 𝑿𝑖 𝑗 , 𝒁𝑖 𝑗 , we have
𝑒−𝑂 (1) (1+|𝜙𝑖 |) ≤ 𝑒𝜷
𝑇
𝑗 𝑿𝑖 𝑗 (𝑠)+𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑠)𝜙𝑖 𝑗 ≤ 𝑒𝑂 (1) (1+|𝜙𝑖 |) ,
𝑒−𝑂 (1)(1+|𝜙𝑖 |)𝑁𝑖 𝑗 (𝜏)𝑒−𝑞𝑖 𝑗 (𝜏) ≤ Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0) ≤ 𝑒𝑂 (1)(1+|𝜙𝑖 |)𝑁𝑖 𝑗 (𝜏)𝑒−𝑞𝑖 𝑗 (𝜏) ,





𝑌𝑖 𝑗 (𝑠)𝑑Λ 𝑗 (𝑠)
}





𝑌𝑖 𝑗 (𝑠)𝑑Λ 𝑗 (𝑠)
}
.
For the second part of Proposition 3.3, choose a positive constant 𝐵0 such that 𝑃( |𝝓 | ≤ 𝐵0) > 0.
Then for bounded ‖Λ 𝑗 ‖𝑉 [0,𝜏] , we have











Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)𝜓(𝜙𝑖;𝚺)𝑑𝜙𝑖
≥ 𝑒−𝑂 (1)
∑𝐽
𝑗=1 𝑁𝑖 𝑗 (𝜏)𝑃(|𝜙𝑖 | ≤ 𝐵0).
We choose 𝑟2(𝑂𝑖) = 𝑒−𝑂 (1)
∑𝐽
𝑗=1 𝑁𝑖 𝑗 (𝜏)𝑃( |𝜙𝑖 | ≤ 𝐵0) > 0 and inequality (3.5) is satisfied.
For inequality (3.4), we note that for any positive integer 𝑚 and 0 < 𝑥1 ≤ · · · ≤ 𝑥𝑚 ≤ 𝑦, there
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(1 + 𝑥𝑖) ≤ 𝜇𝑚 (1 + 𝑦)−𝜅 .
We replace 𝑦 = 𝑞𝑖 𝑗 (𝜏), 𝑚 = 𝑁𝑖 𝑗 (𝜏) and 𝑥 to be 1 + 𝑞𝑖 𝑗 (𝑡) at jumping times. We have
Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)
≤ 𝑒𝑂 (1) (1+|𝜙𝑖 |)𝑁𝑖 𝑗 (𝜏)𝑒−𝑞𝑖 𝑗 (𝜏)
≤ 𝑒𝑂 (1) (1+|𝜙𝑖 |)𝑁𝑖 𝑗 (𝜏)𝜇𝑁𝑖 𝑗 (𝜏)
∏
𝑡≤𝜏
(1 + 𝑞𝑖 𝑗 (𝑡))−𝑑𝑁𝑖 𝑗 (𝑡) (1 + 𝑞𝑖 𝑗 (𝜏))−𝜅







𝑌𝑖 𝑗 (𝑠)𝑑Λ 𝑗 (𝑠)




𝑌𝑖 𝑗 (𝑠)𝑑Λ 𝑗 (𝑠)
)−𝜅
.
We choose 𝑟1(𝑂𝑖) = 𝜇
∑𝐽
𝑗=1 𝑁𝑖 𝑗 (𝜏)
∫
𝑒𝑂 (1) (1+|𝜙𝑖 |)
∑𝐽
𝑗=1 𝑁𝑖 𝑗 (𝜏)𝜓(𝜙𝑖)𝑑𝜙𝑖 in which the inequality (3.4)
holds. 
The next proposition shows some smoothness of Ψ. We denote ¤Ψ as the derivative of Ψ(𝑂𝑖; 𝜃,A)
with respect to 𝜃 and ¤Ψ𝑘 [𝐻 𝑗 ] as the derivative of Ψ(𝑂𝑖; 𝜃,A) along the path (Λ 𝑗 + 𝜖𝐻 𝑗 ), where
𝐻 𝑗 is a function s.t Λ 𝑗 + 𝜖𝐻 𝑗 is increasing and has bounded total variation.
Proposition 3.4 For any (𝜃 (1) , 𝜃 (2)) ∈ Θ, (Λ(1)1 ,Λ
(2)








1 ), · · · ,
(𝐻 (1)𝐽 , 𝐻
(2)
𝐽 ) with uniformly bounded total variations, there exist a random variable F (𝑂𝑖) ∈
66








 ¤Ψ 𝑗 (𝑂𝑖; 𝜃
(1) ,A (1)) [𝐻 (1)𝑗 ]
Ψ(𝑂𝑖; 𝜃 (1) ,A (1))
−
¤Ψ 𝑗 (𝑂𝑖; 𝜃 (2) ,A (2)) [𝐻 (1)𝑗 ]
Ψ(𝑂𝑖; 𝜃 (2) ,A (2))

≤ F (𝑂𝑖)





|Λ(1)𝑗 (𝑠) − Λ
(2)




|𝐻 (1)𝑗 (𝑠) − 𝐻
(2)




In addition, 𝜇𝑖 𝑗 (𝑠;𝑂𝑖) is non-decreasing and E[F (𝑂𝑖)𝜇𝑖 𝑗 (𝑠;𝑂𝑖)] is left-continuous with uniformly
bounded left- and right-derivatives for any 𝑠 ∈ [0, 𝜏].
Proof Recall that
Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0) ≤ 𝑒𝑂 (1)(1+|𝜙𝑖 |)𝑁𝑖 𝑗 (𝜏)𝑒−𝑞𝑖 𝑗 (𝜏) ≤ 𝑒𝑂 (1) (1+|𝜙𝑖 |)𝑁𝑖 𝑗 (𝜏) .
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Besides, the derivatives are satisfied in the following conditions 𝜕𝜕𝛽 𝑗Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)






𝑗 𝑋𝑖 𝑗 (𝑡)+𝜂 𝑗𝑍𝑖 𝑗 (𝑡)𝜙𝑖 𝑗𝑋𝑖 𝑗 (𝑡)𝑑Λ 𝑗 (𝑡)
}
≤ 𝑒𝑂 (1)(1+|𝜙𝑖 |) (1+𝑁𝑖 𝑗 (𝜏)) ,
 𝜕𝜕𝜂 𝑗Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)
 ≤ 𝑒𝑂 (1)(1+|𝜙𝑖 |) (1+𝑁𝑖 𝑗 (𝜏)) ,
 𝜕𝜕Λ 𝑗Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0) [𝐻 𝑗 ]




𝑗 𝑋𝑖 𝑗 (𝑡)+𝜂 𝑗𝑍𝑖 𝑗 (𝑡)𝜙𝑖 𝑗𝑋𝑖 𝑗 (𝑡)𝑑𝐻 𝑗 (𝑡)

≤ 𝑒𝑂 (1)(1+|𝜙𝑖 |) (1+𝑁𝑖 𝑗 (𝜏)) .
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With these bounds of derivative and Mean Value Theorem, we haveΩ𝑖 𝑗 (𝜙𝑖; 𝛾 (1)𝑗 ,Λ 𝑗0) −Ω𝑖 𝑗 (𝜙𝑖; 𝛾 (2)𝑗 ,Λ 𝑗0)
=
 𝜕𝜕𝛾 𝑗Ω𝑖 𝑗 (𝜙𝑖; 𝛾∗𝑗 ,Λ 𝑗0)
 𝛾 (1)𝑗 − 𝛾 (2)𝑗 
≤ 𝑒𝑂 (1) (1+|𝜙𝑖 |) (1+𝑁𝑖 𝑗 (𝜏))
𝛾 (1)𝑗 − 𝛾 (2)𝑗  ,
Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ(1)𝑗0 ) −Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ(2)𝑗0 )
=
 𝜕𝜕Λ 𝑗0Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ∗𝑗0)
 Λ(1)𝑗0 − Λ(2)𝑗0 









≤ 𝑒𝑂 (1) (1+|𝜙𝑖 |) (1+𝑁𝑖 𝑗 (𝜏))
∫ 𝜏
0











Ω𝑖 𝑗 (𝜙𝑖; 𝛾 𝑗 ,Λ 𝑗0)𝜓(𝜙𝑖;Σ(2))𝑑𝜙𝑖

≤
∫ 𝑒𝑂 (1) (1+|𝜙𝑖 |)∑𝐽𝑗=1 𝑁𝑖 𝑗 (𝜏) 𝜕𝜓(𝜙𝑖;Σ∗)𝜕Σ  Σ(1) − Σ(2)  .
The above inequalities use integration by parts and boundedness of covariates 𝑋𝑖 𝑗 and 𝑍𝑖 𝑗 . We can
verify that the other three terms are satisfied the bounds with the same arguments.

The condition requires the smoothness of Ψ and implies that the linear functional
𝐻 𝑗 ↦→ E




is continuous from 𝐵𝑉 [0, 𝜏] to R. Thus there exists a bounded function 𝜈0 𝑗 (𝑠; 𝜃,A) such that
E






𝜈0 𝑗 (𝑠; 𝜃,A)𝑑𝐻 𝑗 (𝑠), (3.8)
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which will be used in Proposition 3.6.
Proposition 3.5 The model is identifiable. That is, if
𝐿 (𝜃,A;𝐷) = 𝐿 (𝜃′,A′;𝐷), (3.9)
for all possible 𝐷 = {𝑋 (𝑡), 𝑍 (𝑡), 𝑌 𝑗 (𝑡), 𝑁 𝑗 (𝑡), 𝑗 = 1, 2, · · · , 𝐽; 𝑡 ∈ [0, 𝜏]}, then (𝜃,A) = (𝜃′,A′).
Proof This is proved in Theorem 3.1. 
Proposition 3.6 There exist function 𝜁0 𝑗 (𝑠; 𝜃0,A0) ∈ 𝐵𝑉 [0, 𝜏], 𝑗 = 1, · · · , 𝐽 and a matrix
𝜁0𝜃 (𝜃0,A0) such thatE [ ¤Ψ𝜃 (𝑂𝑖; 𝜃,A)Ψ(𝑂𝑖; 𝜃,A) − ¤Ψ𝜃 (𝑂𝑖; 𝜃0,A0)Ψ(𝑂𝑖; 𝜃0,A0)
]






𝜁0 𝑗 (𝑠; 𝜃0,A0)𝑑 (Λ 𝑗 − Λ0 𝑗 )
 = 𝑜 ©­«|𝜃 − 𝜃0 | +
𝐽∑
𝑗=1
‖Λ 𝑗 − Λ0 𝑗 ‖𝑉 [0,𝜏]
ª®¬ .
(3.10)











𝜈0 𝑗𝑚 (𝑠, 𝑡; 𝜃0,A0)𝑑 (Λ𝑚 − Λ0𝑚)(𝑡)
 = 𝑜 ©­«|𝜃 − 𝜃0 | +
𝐽∑
𝑗=1
‖Λ 𝑗 − Λ0 𝑗 ‖𝑉 [0,𝜏]
ª®¬ ,
(3.11)
where 𝜈0 𝑗𝑚 is a bounded bivariate function and 𝜈0 𝑗𝜃 is a 𝑑−dimensional bounded function. Fur-
thermore, there exists a constant 𝑐3 such that
|𝜈0 𝑗𝑚 (𝑠, 𝑡1; 𝜃0,A0) − 𝜈0 𝑗𝑚 (𝑠, 𝑡2; 𝜃0,A0) ≤ 𝑐3 |𝑡1 − 𝑡2 |,
for any 𝑠 ∈ [0, 𝜏] and any 𝑡1, 𝑡2 ∈ [0, 𝜏].
Proof
70
We calculate from definition that




𝑚=1 Ω𝑖𝑚 (𝜙; 𝛾𝑚,Λ𝑚)𝜓(𝜙;Σ)∫
𝜙
∏𝐽
𝑚=1 Ω𝑖𝑚 (𝜙; 𝛾𝑚,Λ𝑚)𝜓(𝜙;Σ)𝑑𝜙
𝑌𝑖 𝑗 (𝑠)𝑒𝛽 𝑗𝑋𝑖 𝑗 (𝑠)+𝜂 𝑗𝑍𝑖 𝑗 (𝑠)𝜙𝑑𝜙
]
.






𝜈0 𝑗 (𝑠, 𝑡; 𝜃0,A0) [Λ𝑚 − Λ0𝑚]
 = 𝑜 ©­«|𝜃 − 𝜃0 | +
𝐽∑
𝑗=1
‖Λ 𝑗 − Λ0 𝑗 ‖𝑉 [0,𝜏]
ª®¬ .
Define 𝜈0 𝑗𝜃 =
𝜕𝜈0 𝑗
𝜕𝜃 and 𝜈0 𝑗𝑚 to be derivative of 𝜈0 𝑗 with respect to Λ𝑚 along the direction Λ𝑚−Λ0𝑚
and we reach equation (3.11). For equation (3.10), we can derive it by verifying the Lipschitz
continuity of 𝜈0𝑘𝑚. 
Proposition 3.7 ((Second Identifiability Condition)) If for some 𝑣 ∈ R𝑑 and ℎ 𝑗 ∈ 𝐵𝑉 [0, 𝜏], 𝑗 =




ℎ 𝑗 (𝑡)𝑌𝑖 𝑗 (𝑡)𝑑𝑁𝑖 𝑗 (𝑡) +
¤Ψ𝜃 (𝑂𝑖; 𝜃0,A0)𝑇𝑣 +
∑𝐽
𝑗=1
¤Ψ 𝑗 (𝑂𝑖; 𝜃0,A0) [
∫
ℎ 𝑗𝑑Λ0 𝑗 ]
Ψ(𝑂𝑖; 𝜃0,A0)
= 0, (3.12)
almost surely, then 𝑣 = 0 and ℎ 𝑗 = 0, 𝑗 = 1, · · · , 𝐽.
Proof Similar arguments in Proposition 3.5. 
This proposition shows that the Fisher information matrix along any finite-dimensional submodel
is non-singular.
Proposition 3.8 There exists a neighborhood of (𝜃0,A0) such that for (𝜃,A) in this neighbor-
hood, the first and second derivatives of logΨ(𝑂𝑖; 𝜃,A) with respect to 𝜃 and along the path
Λ 𝑗 + 𝜖𝐻 𝑗 with respect to 𝜖 satisfy the inequality in (3.6) .
Proof This is similar to Proposition 3.4 based on 𝜕
2Ψ(𝑂𝑖 ;𝜃,A)
𝜕𝜃2
and the first and second derivatives
of Ψ(𝑂𝑖, 𝜃,A0 + 𝜖𝐻) with respect to 𝜖 . 
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Theorem 3.2 (Consistency) Under assumptions (A1)-(A4),





|Λ̂𝑛 𝑗 − Λ0 𝑗 |
𝑎.𝑠.→ 0.
Proof The entire proof is complex and we leave the technical details in Appendix. We gives a
sketch of the proof here. The entire proof consists of three steps.
• Step 1: The non-parametric maximum likelihood estimators Λ̂ 𝑗 (𝜏) < ∞ for 𝑗 = 1, · · · , 𝐽










𝑌𝑖 𝑗 (𝑡)𝑑Λ 𝑗 (𝑡)
}−𝑐1
.
If Λ 𝑗 (𝜏) = ∞ for some j, the condition (A2) is violated.
• Step 2: Show lim sup𝑛 Λ̂ 𝑗 (𝜏) < ∞ almost surely.
• Step 3: As Λ̂ 𝑗 is bounded and monotone, Λ̂ 𝑗 becomes weakly compact. If we apply Helly’s
Selection Theorem, we can select a subsequence for any subsequence, s.t the selected sub-
sequence point-wise converges to some monotone function Λ∗𝑗 . Similar, we define that 𝜃
converges to 𝜃∗. If we can prove that Λ∗𝑗 = Λ0 𝑗 and 𝜃
∗ = 𝜃0, the consistency will hold.

Before we state the asymptotic normality of the estimators, we need to clarify some notations.
Let 𝑈 be any set, the space 𝑙∞(𝑈) is the collection of all uniformly bounded, real functions on
𝑈. For any positive real numbers 𝑎, 𝑏, 𝐵𝑉 [𝑎, 𝑏] is the collection of real functions with bounded
total variations on [𝑎, 𝑏]. Besides, we define V = {𝑣 ∈ R𝑑; ‖𝑣‖ ≤ 1} and 𝑄 = {ℎ : ‖ℎ‖𝑉 [0,𝜏] ≤
1, ℎ(0) = 0}, where ‖ · ‖𝑉 [0,𝜏] is the total variation of function ℎ in [0, 𝜏]. Actually, Λ̂𝑛 𝑗 , as
a bounded linear functional operator, is an element in 𝑙∞(𝑄) by Λ̂𝑛 𝑗 (ℎ) =
∫ 𝜏
0 ℎ(𝑠)𝑑Λ̂𝑛 𝑗 (𝑠) for
ℎ ∈ 𝑄. With these notations, we can identify (𝜃𝑛−𝜃0, Â𝑛−A0) as a random element in 𝑙∞(V×𝑄𝐽)




0 ℎ 𝑗 (𝑠)𝑑 (Λ̂𝑛, 𝑗0 −Λ0, 𝑗0) (𝑠) for some 𝑣 ∈ V and ℎ 𝑗 ∈ 𝑄.
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Theorem 3.3 (Asymptotically Normality) Under assumptions (A1)-(A5), we have
√
𝑛(𝜃𝑛 − 𝜃0, Â𝑛 − A0)
𝑑→ G,
in 𝑙∞(V × 𝑄𝐽), where G is a continuous zero-mean Gaussian process. Furthermore, the limiting
covariance matrix of
√
𝑛(𝜃𝑛 − 𝜃0) attains the semi-parametric efficiency bound.




𝑛(Â𝑛−A0) are joint asymptotically normal in space
𝑙∞(V×𝑄𝐽). For asymptotic variance, let 𝐼𝑛 be observed information matrix of log-likelihood with









0 ℎ 𝑗 (𝑠)𝑑 (Λ̂ 𝑗0 − Λ0 𝑗0)(𝑠)
}











𝑘=1 ℎ 𝑗 (𝑡𝑖 𝑗 𝑘 )Λ̂ 𝑗0(𝑡𝑖 𝑗 𝑘 )
}
, while the latter one can be estimated
by the following corollary.
Corollary 3.1 Under assumptions (A1)-(A5), 𝐼𝑛 is invertible and
sup
𝑣∈V,ℎ1,··· ,ℎ𝐽∈𝑄














where AVar denotes asymptotic variance and ℎ̄ 𝑗 is the vector consisting of the values of ℎ 𝑗 (·) at
the observed event times.
We can also estimate the asymptotic variance matrix Σ of
√
𝑛(𝜃−𝜃0) independently with profile
log-likelihood function:
Theorem 3.4 Let 𝑃𝐿𝑛 (𝜃) be the profile log-likelihood function for 𝜃. Under the assumptions (A1)-
(A5), for any 𝜖𝑛 = 𝑂𝑝 (𝑛−1/2) and any vector 𝑣,




Furthermore, 2{𝑃𝐿𝑛 (𝜃𝑛) − 𝑃𝐿𝑛 (𝜃0)}
𝑑→ 𝜒2𝑑 .
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Chapter 4: Real Data Analyses with Generalized Random Effect Model
We use an electronic health record dataset to investigate the application of dynamic random effect
model in the last chapter. The data comes from a healthcare and insurance company. It includes
patient-level prescription and diagnosis information in around 40 million people with almost a
decade observation period. The diagnosis information is recorded with diagnosis date and type
with ICD-9 code systems. For drug prescription, we can extract the name of the prescribed drug
with brand name, the dates when the drugs are prescribed, and the length of period provided by
clinicians. The unit for both dates are days. We assume the patient starts to be in drug exposure in
the prescription day and keeps it until reaching the assigned number of days. If a new prescription
is filled before the end of assigned number of days, we update the prescription length by the longer
one.
We consider Myocardial Infarction (MI) and Angiotensin-converting-enzyme inhibitors (ACE
inhibitors) as two event types. Myocardial Infarction is a medical emergency and often occurs
when a blood clot blocks blood flow to the heart. Angiotensin-converting-enzyme inhibitor (ACE
inhibitor) is a class of medication used primarily for the treatment of high blood pressure and heart
failure. A meta analysis [2] shows evidence that an ACE inhibitor within 3 to 16 days of infarction
can slow the progression of cardiovascular disease and improve the survival rate. Our objective
is to illustrate the strength of casual relationship between disease diagnosis and drug prescription
with dynamic random effect.
There were 142, 234 patients who have at least one MI and 1, 715, 301 patients who have at
least one ACE Inhibitor prescription during their observation periods. The distribution of event
numbers for patients are presented in Figure 4.1 and 4.2. The average number of MI diagnosis
events and ACE Inhibitor prescription events are 4.73 and 12.56, respectively, showing recurrent













Figure 4.1: Histogram of MI frequency
prescription events with average number 14.61, which is a little higher than its population average.
Recall the intensity
𝜆𝑖1(𝑡 |𝜙𝑖1, F𝑡) =𝑌𝑖 (𝑡)𝑒𝛼1+𝜷
𝑇
1 𝑿𝑖1 (𝑡)+𝜼𝑇1 𝒁𝑖1 (𝑡)𝜙𝑖1 ,
𝜆𝑖2(𝑡 |𝜙𝑖2, F𝑡) =𝑌𝑖 (𝑡)𝑒𝛼2+𝜷
𝑇
2 𝑿𝑖2 (𝑡)+𝜼𝑇2 𝒁𝑖2 (𝑡)𝜙𝑖2 .
(4.1)
As there is no obvious start point, we use constant baseline 𝛼1, 𝛼2 for both events. Let 𝑇𝑖 𝑗 (𝑡)
denote the latest occurring time point of event type 𝑗 before time 𝑡. If no event occurs before
time 𝑡, we define 𝑇𝑖 𝑗 (𝑡) = 0. We assume the random effect covariate 𝑍𝑖 𝑗 (𝑡) is based on the time
gap between 𝑡 and 𝑇𝑖 𝑗 (𝑡) and fixed effect covariate 𝑋𝑖 𝑗 (𝑡) is based on both the time gap between 𝑡
and 𝑇𝑖1(𝑡) and the time gap between 𝑡 and 𝑇𝑖2(𝑡). In other word, 𝑍𝑖 𝑗 (𝑡) is a function of 𝑡 − 𝑇𝑖 𝑗 (𝑡)
and 𝑋𝑖 𝑗 (𝑡) is a function of (𝑡 − 𝑇𝑖1(𝑡), 𝑡 − 𝑇𝑖2(𝑡)). Besides time varying covariates, the fixed effect
covariates also include some time-independent features, e.g. gender and age. To reach the model











Figure 4.2: Histogram of ACE Inhibitor frequency
adopt piecewise linear functions for both 𝑋𝑖 𝑗 (𝑡) and 𝑍𝑖 𝑗 (𝑡). Above all, the covariates can be
𝜷𝑇1 𝑿𝑖1(𝑡) =𝛽𝑔𝑒𝑛𝑑𝑒𝑟1 × gender + 𝛽𝑎𝑔𝑒1 × age + 𝛽2→1I(𝑇𝑖2 > 0)I(𝑡 − 𝑇𝑖2 < 𝑊1)
+ 𝜷𝑇1→1
©­­­­­­­­«
I(𝑇𝑖1 > 0) (𝑡 − 𝑇𝑖1(𝑡) − 𝜉𝑥10)+
I(𝑇𝑖1 > 0) (𝑡 − 𝑇𝑖1(𝑡) − 𝜉𝑥11)+
...
I(𝑇𝑖1 > 0)(𝑡 − 𝑇𝑖1(𝑡) − 𝜉𝑥1𝐿𝑥1 )+
ª®®®®®®®®¬
,
𝜷𝑇2 𝑿𝑖2(𝑡) =𝛽𝑔𝑒𝑛𝑑𝑒𝑟2 × gender + 𝛽𝑎𝑔𝑒2 × age + 𝛽1→2I(𝑇𝑖1 > 0)I(𝑡 − 𝑇𝑖1 < 𝑊2)
+ 𝜷𝑇2→2
©­­­­­­­­«
I(𝑇𝑖2 > 0)(𝑡 − 𝑇𝑖2(𝑡) − 𝜉𝑥20)+
I(𝑇𝑖2 > 0)(𝑡 − 𝑇𝑖2(𝑡) − 𝜉𝑥21)+
...





𝜼𝑇𝑗 𝒁𝑖 𝑗 (𝑡) =1 + 𝜼𝑇𝑗→ 𝑗
©­­­­­­­­­«
I(𝑇𝑖 𝑗 > 0) (𝑡 − 𝑇𝑖 𝑗 (𝑡) − 𝜉𝑧𝑗0)+
I(𝑇𝑖 𝑗 > 0) (𝑡 − 𝑇𝑖 𝑗 (𝑡) − 𝜉𝑧𝑗1)+
...
I(𝑇𝑖 𝑗 > 0)(𝑡 − 𝑇𝑖 𝑗 (𝑡) − 𝜉𝑧𝑗 𝐿𝑧𝑗 )+
ª®®®®®®®®®¬
.
The nodes for the piecewise linear function are calculated based on the quantiles of time gap
between two consecutive time points of the events. We choose the number of nodes by minimizing
the BIC criterion.
Table 4 and Fig 4.3 show the estimation results. In table 4, we compare three types of model
and show some parameters estimation and criterion including AIC and BIC. The model 𝐼 𝐼 𝐼 in
the third column is the model we introduce above, which implement the correlated and dynamic
random effect. The model 𝐼 in the first column has the similar model setting except the random
effect is uncorrelated but dynamic. The model 𝐼 𝐼 in the second column uses correlated but constant
random effect. The table 4 shows the estimation of baseline parameters 𝛼1, 𝛼2, coefficients of
time-independent covariates age and gender, the relative risk parameters of fixed effect from drug
prescription event to disease diagnosis event 𝛽2→1 and the reverse 𝛽1→2, the hyperparameters of
random effect distribution 𝜎1, 𝜎2, 𝜌 and criterion AIC and BIC.
The coefficients of time-independent covariates age and gender are all positive, showing that
older patients and male patients are more likely to have MI diagnosis and ACE Inhibitor prescrip-
tion. As for the relative risk parameters of fixed effect from drug prescription event to disease
diagnosis event, we can find this estimation is significantly positive in model 𝐼 but significantly
negative in model 𝐼 𝐼 and 𝐼 𝐼 𝐼. As we learned from medical literature, ACE inhibitor can reduce the
risk of MI in some sense, which satisfy the estimation results in model 𝐼 𝐼 and 𝐼 𝐼 𝐼 which implement
correlated random effect. Actually, in Chapter 2, we have proved that when the random effect is
correlated with covariates, the estimation will be biased under independence assumption. The es-
timation of correlation coefficients 𝜌 in random effect distribution is positive. This means that the
events of MI diagnosis and ACE inhibitor prescription are likely to happen together, which satisfies
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the common nature. Among three models, the model 𝐼 𝐼 𝐼 gives the best performance with respect
to both AIC and BIC, which support the necessity of correlated and dynamic random effects.
The Fig 4.3 gives the estimated random effect and fixed effect functions, (a) 𝜼𝑇1→1𝒁𝑖1(𝑡) (b)
𝜷𝑇1→1𝑿𝑖1(𝑡) (c) 𝜼𝑇2→2𝒁𝑖2(𝑡) (d) 𝜷
𝑇
2→2𝑿𝑖2(𝑡) ,in model 𝐼 𝐼 𝐼. The self fixed effect of MI diagnosis
𝜷𝑇1→1𝑿𝑖1(𝑡) is negative and increases at the first 21 days and then decreases to zero as time goes.
The self random effect 𝜼𝑇1→1𝒁𝑖1(𝑡) is below 1 at first, which is because patients would not go to
the hospital immediately after the a diagnosis. For ACE inhibitor prescription, the self fixed effect
𝜷𝑇2→2𝑿𝑖2(𝑡) shows peak at 30 days which meets the fact that most prescriptions provide 30 days
of medication. The self random effect 𝜼𝑇2→2𝒁𝑖2(𝑡) are below 1 all the time. This shows that after a
prescription event, the heterogeneity or unobserved covariate has relative small effects on the risk
of next prescription event.
Model 𝐼 Model 𝐼 𝐼 Model 𝐼 𝐼 𝐼
𝛼1 -16.11 (-16.56,-15.66) -17.25 (-17.73,-16.77) -16.88 (-17.33,-16.43)
𝛼2 -12.32 (-12.42,-12.22) -12.91 (-13.01,-12.81) -12.21 (-12.31,-12.11)
𝛽gender1 0.65 (0.57,0.73) 0.75 (0.66,0.84) 0.67 (0.58,0.75)
𝛽age1 0.81 (0.77,0.85) 1.02 (0.98,1.06) 0.94 (0.90,0.98)
𝛽gender2 0.28 (0.24,0.32) 0.42 (0.38,0.46) 0.29 (0.26,0.31)
𝛽age2 0.61 (0.59,0.62) 0.81 (0.80,0.82) 0.63 (0.62,0.64)
𝛽2→1 0.59 (0.47,0.71) -0.27 (-0.38,-0.16) -0.22(-0.33,-0.10)
𝛽1→2 0.91 (0.70,1.12) 0.59 (0.47,0.71) 0.57(0.46,0.68)
𝜎1 1.91 (1.78,2.05) 2.03 (1.85,2.21) 2.01 (1.88,2.14)
𝜎2 2.05 (2.02,2.08) 1.98 (1.92,2.04) 2.10 (2.07,2.13)
𝜌 0 0.63 (0.59,0.67) 0.57 (0.52,0.62)
-1𝑛 log-likelihood 2.7787 2.7453 2.7267
1
𝑛BIC 5.5599 5.4922 5.4559
1
𝑛AIC 5.5578 5.4909 5.4538
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Figure 4.3: Results of time varying covariates functions for fixed effect and random effect, (a)
𝜼𝑇1→1𝒁𝑖1(𝑡) (b) 𝜷
𝑇





In this thesis, we discuss the event history analysis in multivariate longitudinal observational
databases (LODs) and its application in postmarketing surveillance to identify and measure the
relationship between events of health outcomes and drug exposures. The LODs contain a series
of repeated observations of the same subjects over time and play a key role in finance, online
assessment and clinical research. The scale and complexity of LODs require that the statistical
analysis can explain the correlation structure of within-individual heterogeneity. If such correlation
is ignored, the inferences such as statistical tests or estimation can be grossly invalid. The SCCS
model [29, 30] implements an individual-level baseline constant and each individual serves as their
own control. Although this method is good at explaining heterogeneity and eliminating bias, the
SCCS method does not make full advantage of the observational databases. In this connection,
the SCCS method may lead to loss of efficiency and fail in application of more general situations,
especially in multivariate data.
We propose a multivariate proportional intensity model with random effects for multivariate
longitudinal databases. A central component of the multivariate random effect model is its flexible
representation to describe the association between multiple events when the independence assump-
tion is violated. Besides, the random effect part can help explain the heterogeneity or unobserved
covariates of individuals in datasets, achieved by high dimensional Log-Gaussian random effect
with a more flexible form. For the estimation of the results, we adopt the Bayesian approach by
Markov chain Monte Carlo method to get a series samples of target full semi-parametric likelihood.
The simulation of different random effect settings illustrate the necessity of correlation structure
within the unobserved covariates, especially in cases when covariates and outcomes are not in-
dependent. For real data application in Observational Outcomes Medical Partnership (OMOP)
project, the performance of our proposed model and other existing model were shown by receiver
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operating characteristic (ROC) metrics and our model performs best in an electronic health record
(EHR) dataset.
Besides, we extend our multivariate proportional intensity model to dynamic random effect.
This is due to the fact that the hidden factors of events can be influenced by the occurrence of
the events. With such dynamic design, we develop the consistency and asymptotically normal-
ity theory of semi-parametric maximum likelihood estimation. With an electronic health record
database, a detailed illustration of the proposed method is done with the clinical event Myocardial
Infarction (MI) and drug treatment of Angiotensin-converting-enzyme (ACE) inhibitors, showing
the dynamic effect of unobserved heterogeneity.
While we present the method using medical databases, the method is widely applicable. For
example, in shopping website data, we are interested in their behaviors on the website and the asso-
ciation structure between these behaviors which gives some suggestions for our strategy. Besides,
the method can be used in finance to better understand the effect of economic stocks.
In future works, we will explore the more complex structure of unobserved covariates in event
history analysis. We discuss the dynamic and correlated random effect structure above. When the
number of events grows, the dimension of unobserved covariates also increases. This may lead
some overfitting problems. One of our future work is dealing with dimension analysis. Another
future direction is to study the performance of the methods under sparsity conditions. The spar-
sity condition is really common in medical databases. Some adverse events, e.g rare disease and
their orphan drugs, have really low frequency of occurrences. We are interested in the theory and
application of random effect methods in such design.
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